"","pmid","doi","title","abstract","year","month","day","jabbrv","journal","keywords","lastname","firstname","address","email"
"1","32734670","10.1111/jcpt.13222","Characteristics of Clinical Trials relating to COVID-19 registered at ClinicalTrials.gov.","Since the beginning of the COVID-19 outbreak in China in December 2019, the epidemic has continued to spread globally. Despite continuous reports of clinical trials being launched, no studies have yet systematically summarized and analysed their characteristics. Our objective is to do this by reviewing trials registered at ClinicalTrials.gov. We searched the ClinicalTrials.gov database and retrieved all clinical trials on COVID-19 registered up to and including 3 April 2020. We summarized the ch","2020","12","21","J Clin Pharm Ther","Journal of clinical pharmacy and therapeutics","COVID-19; SARS-CoV-2; characteristics analysis; clinical trial registration; Antimalarials; Antiviral Agents; COVID-19; Clinical Trials as Topic; Databases, Factual; Humans; Research Design","Wang","Yuhui","Department of Pharmacy, Zhengzhou University First Affiliated Hospital, Zhengzhou, China",NA
"2","32731192","10.1016/j.diagmicrobio.2020.115078","COVID-19: Understanding the science of antibody testing and lessons from the HIV epidemic.","Potential pitfalls in the development, deployment and interpretation of antibody tests for COVID-19 are discussed. Lessons learned from the experience with the introduction of antibody tests for HIV are highlighted.Each test will need to be separately vetted for performance and clinical implementation based upon rigorous clinical trial data. The issues we highlight will also be similarly important for vaccine and therapeutic drug efficacy trials.","2020","08","17","Diagn Microbiol Infect Dis","Diagnostic microbiology and infectious disease","Antibody-dependent enhancement; Cross-reactivity; False positive; HIV; Laboratory; SARS-CoV-2; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Coronavirus Infections; HIV Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sensitivity and Specificity; United States; United States Food and Drug Administration","Weiss","Stanley H","Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, U.S.A.","weiss@rutgers.edu"
"3","32729281","10.34172/ijhpm.2020.130","COVID-19 Intervention Scenarios for a Long-term Disease Management.","The first outbreak of coronavirus disease 2019 (COVID-19) was successfully restrained in many countries around the world by means of a severe lockdown. Now, we are entering the second phase of the pandemics in which the spread of the virus needs to be contained within the limits that national health systems can cope with. This second phase of the epidemics is expected to last until a vaccination is available or herd immunity is reached. Long-term management strategies thus need to be developed. ","2021","02","15","Int J Health Policy Manag","International journal of health policy and management","Agent-Based Model; Containment; Corona Virus; Pandemic; Scenario Analysis; Simulation; COVID-19; Communicable Disease Control; Contact Tracing; Decision Making; Delivery of Health Care; Disease Management; Disease Outbreaks; Humans; Models, Theoretical; Pandemics; Physical Distancing; SARS-CoV-2; Social Isolation","Wallentin","Gudrun","Department of Geoinformatics - Z_GIS, University of Salzburg, Salzburg, Austria",NA
"4","32727468","10.1186/s12917-020-02476-3","A new passive immune strategy based on IgY antibodies as a key element to control neonatal calf diarrhea in dairy farms.","Neonatal diarrhea remains one of the main causes of morbi-mortality in dairy calves under artificial rearing. It is often caused by infectious agents of viral, bacterial, or parasitic origin. Cows vaccination and colostrum intake by calves during the first 6...h of life are critical strategies to prevent severe diarrhea but these are still insufficient. Here we report the field evaluation of a product based on IgY antibodies against group A rotavirus (RVA), coronavirus (CoV), enterotoxigenic Esc","2020","09","18","BMC Vet Res","BMC veterinary research","IgY antibody; Infectious neonatal calf diarrhea; Passive treatment; Rotavirus; Animals; Animals, Newborn; Antibodies, Bacterial; Antibodies, Protozoan; Antibodies, Viral; Cattle; Cattle Diseases; Cryptosporidiosis; Dairying; Diarrhea; Immunization, Passive; Immunoglobulins; Immunotherapy","Vega","Celina Guadalupe","Incuinta, Instituto Nacional de Tecnolog..a Agropecuaria (INTA), Buenos Aires, Argentina. vega.celina@inta.gob","vega.celina@inta.gob.ar"
"5","32726230","10.5811/westjem.2020.5.47658","Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.","In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is neither a vaccine nor proven treatment for COVID-19, there is currently an urgent need for effective pharmacotherapy. To address the need for an effective treatment of SARS-CoV-2 during the worldwide pandemic, this systematic review of intraveno","2020","08","05","West J Emerg Med","The western journal of emergency medicine","Adenosine Monophosphate; Administration, Intravenous; Alanine; Antiviral Agents; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome","Musa","Arif","Wayne State University School of Medicine, Detroit, Michigan",NA
"6","32725080","10.1590/1414-431x202010475","Past, present, and future of COVID-19: a review.","SARS-CoV-2 has recently emerged, becoming a global threat, affecting directly all human beings owing to its morbidity and mortality and indirectly, due to the enormous economic and psychological impact produced by social isolation, the most effective measure so far, but unsustainable for a long period. The scientific effort to understand and control SARS-CoV-2 transmission and clinical impact has been huge, and important achievements are highlighted in this review. Diagnosis is central and is th","2020","07","31","Braz J Med Biol Res","Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Evaluation; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Romano","C M","Hospital das Clinicas HCFMUSP (LIM52), Faculdade de Medicina, Universidade de S..o Paulo, S..o Paulo, SP, Brasil",NA
"7","32723801","10.1124/jpet.120.000123","Drug Discovery Strategies for SARS-CoV-2.","Coronavirus disease 2019 (COVID-19) is a novel disease caused by the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 virus that was first detected in December of 2019 in Wuhan, China, and has rapidly spread worldwide. The search for a suitable vaccine as well as effective therapeutics for the treatment of COVID-19 is underway. Drug repurposing screens provide a useful and effective solution for identifying potential therapeutics against SARS-CoV-2. For example, the experimental drug r","2020","10","01","J Pharmacol Exp Ther","The Journal of pharmacology and experimental therapeutics","Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Discovery; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines; Virus Internalization; Virus Replication","Shyr","Zeenat A","National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland",NA
"8","32722908","10.1056/NEJMoa2024671","Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.","Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important to evaluate in nonhuman primates. Nonhuman primates received 10 or 100 ..g of mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein of SARS-CoV-2, or no vaccine. Antibody and T-cell responses were assessed before upper- and lower-airway challenge with SARS-C","2020","10","27","N Engl J Med","The New England journal of medicine","Animals; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; CD4 Antigens; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Disease Models, Animal; Dose-Response Relationship, Immunologic; Immunization, Passive; Lung; Macaca mulatta; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Viral Load; Viral Vaccines; Virus Replication","Corbett","Kizzmekia S","From the Vaccine Research Center (K.S.C., B. Flynn, K.E.F., J.R.F., S.B.-B., A.P.W., B. Flach, S. O'Connell, A.T.N., N.D., M.M.D., N.N.N., G.S.A., D.R.F., E.L., N.A.D.-R., B.C.L., M.K.L., S. O'Dell, S.D.S., E.P., L.A.C., C.Y., J.-P.M.T., W.S., Y.Z., O.M.A., L.W., A.P., E.S.Y., K.L., T.Z., I.-T.T., A.W., I.G., L.N., R.A.G., R.J.L., J.I.M., W.-P.K., K.M.M., T.J.R., J.E.L., M.R.G., P.D.K., J.R.M., A.M., N.J.S., M.R., R.A.S., B.S.G.), the Infectious Disease Pathogenesis Section (K.W.B., M.M., B.M.N., M.G.L.), and the Biostatistics Research Branch, Division of Clinical Research (M.C.N.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, and Bioqual (H.A., L.P., A.V.R., S.B., J.G., T.P.-T., A.S., T.-A.C., A. Cook, A.D., K.S., I.N.M.) and the Public Health Service Commissioned Corps (M.R.G.), Rockville - both in Maryland",NA
"9","32719684","10.3389/fimmu.2020.01581","COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.","To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. Our literature and clinical trial survey showed that the whole virus, as well as the spike (S) protein, nucleocapsid (N) protein, and membrane (M) protein, have been tested for vaccine development against SARS and MERS. However, these vaccine candidates might lack the induction of complete protection and have safe","2020","08","03","Front Immunol","Frontiers in immunology","COVID-19; S protein; machine learning; non-structural protein 3; reverse vaccinology; vaccine; vaxign; vaxign-ML; Animals; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Epitopes, B-Lymphocyte; Humans; Immunogenicity, Vaccine; Machine Learning; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Proteins; Viral Vaccines","Ong","Edison","Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, United States",NA
"10","32719619","10.3389/fphys.2020.00820","While We Wait for a Vaccine Against SARS-CoV-2, Why Not Think About Available Drugs?","At the time of reception of this article (April 2, 2020), efforts to develop a specific vaccine against SARS-Cov-2, the causative agent of the coronavirus disease 2019 (COVID-19), had just begun trial phase 1, but full validation of this and other current developments is likely to take many more months to reach completion. The ongoing pandemic constitutes a major health burden of world proportions that is also having a devastating impact on whole economies worldwide, the knock-on effects of whic","2020","12","01","Front Physiol","Frontiers in physiology","ACE2; COVID-19; SARS-CoV-2; coronavirus; design drugs; prophylaxis","Barrantes","Francisco J","Biomedical Research Institute (BIOMED), Argentina Pontifical Catholic University of Argentina (UCA) and National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina",NA
"11","32718772","10.1016/j.cllc.2020.06.024","Considerations for the Surgical Management of Early Stage Lung Cancer During the COVID-19 Pandemic.","The highly transmissible novel coronavirus (COVID-19) has infected over 8.8 million people globally and has upended the delivery of health care in the United States, creating unprecedented challenges to providing care to patients with early stage non-small cell lung cancer (NSCLC). The initial surge of patients with COVID-19 that have flooded hospitals has put a strain on physical space, workforce, and supplies. In addition, social distancing and the risk of COVID-19 transmission has created sig","2021","01","29","Clin Lung Cancer","Clinical lung cancer","COVID-19; Non...small-cell lung cancer; Protection; Surgery; Testing","Merritt","Robert E","Thoracic Surgery Division, The Ohio State University Wexner Medical Center, Columbus, OH. Electronic address: Robert.Merritt@osumc","Robert.Merritt@osumc.edu"
"12","32718020","10.3390/ijms21155224","Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials.","The ongoing pandemic of coronavirus disease-2019 (COVID-19) is being caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The disease continues to present significant challenges to the health care systems around the world. This is primarily because of the lack of vaccines to protect against the infection and the lack of highly effective therapeutics to prevent and/or treat the illness. Nevertheless, researchers have swiftly responded to the pandemic by advancing old and new po","2020","08","12","Int J Mol Sci","International journal of molecular sciences","ACE2; COVID-19; SARS-CoV-2; TMPRSS2; coronavirus; endocytosis; spike protein; viral entry; viral fusion; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Peptides; Pneumonia, Viral; Polysaccharides; SARS-CoV-2; Small Molecule Libraries; Virus Attachment; Virus Internalization","Al-Horani","Rami A","Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125, USA",NA
"13","32717321","10.1016/j.ygeno.2020.07.033","Genomics approaches to synthesize plant-based biomolecules for therapeutic applications to combat SARS-CoV-2.","COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is devastative to the humankind for which neither vaccines nor precise therapeutic molecules for treatment are identified. The search for new drugs and repurposing of existing drugs are being performed; however, at the same time, research on plants to identify novel therapeutic compounds or testing the existing ones is progressing at a slower phase. In this context, genomics and biotechnology offer various tools and ","2020","12","31","Genomics","Genomics","Coronavirus; Genetic manipulation; Genomics; Plant-based drugs; SARS-CoV-2; Therapeutics; Antiviral Agents; COVID-19; Gene Editing; Genomics; Humans; Plants; Plants, Genetically Modified","Sharma","Namisha","National Institute of Plant Genome Research, Aruna Asaf Ali Marg, New Delhi 110067, India",NA
"14","32711692","10.1016/S1473-3099(20)30458-8","Monitoring approaches for health-care workers during the COVID-19 pandemic.","Health-care workers are crucial to any health-care system. During the ongoing COVID-19 pandemic, health-care workers are at a substantially increased risk of becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and could come to considerable harm as a result. Depending on the phase of the pandemic, patients with COVID-19 might not be the main source of SARS-CoV-2 infection and health-care workers could be exposed to atypical patients, infected family members, conta","2020","10","13","Lancet Infect Dis","The Lancet. Infectious diseases","Betacoronavirus; COVID-19; Coronavirus Infections; Guidelines as Topic; Health Personnel; Health Services Accessibility; Humans; Infection Control; Occupational Exposure; Pandemics; Pneumonia, Viral; Return to Work; Risk Management; SARS-CoV-2","Bielicki","Julia A","Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St George's University of London, London, UK","julia.bielicki@ukbb.ch"
"15","32710003","10.1038/d41586-020-02174-y","Coronavirus vaccines leap through safety trials - but which will work is anybody's guess.",NA,"2020","09","04","Nature","Nature","Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Coronavirus Infections; Drug Industry; Genetic Vectors; Humans; Pandemics; Patient Safety; Pneumonia, Viral; SARS-CoV-2; T-Lymphocytes; Treatment Outcome; Uncertainty; Viral Vaccines","Callaway","Ewen",NA,NA
"16","32706390","10.1002/jmv.26338","The mechanistic rationale of drugs, primary endpoints, geographical distribution of clinical trials against severe acute respiratory syndrome-related coronavirus-2: A systematic review.","There are numerous ongoing studies assessing treatment options for preventing, treating, and managing complications of coronavirus disease-2019 disease. The objective of this study was to do a systematic review and critical appraisal of the ongoing clinical trials with an aim to provide insight into the various interventions tested, clinical rationale, geographical distribution of the trials as well as the endpoints assessed in the studies. ClinicalTrials.gov, World Health Organization Internati","2021","01","14","J Med Virol","Journal of medical virology","COVID-19; clinical trials; hydroxychloroquine; systematic review; vaccines; COVID-19; China; Clinical Trials as Topic; Endpoint Determination; Geography; Humans; United States","Venkatesulu","Bhanu Prasad","Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan",NA
"17","32702822","10.1097/MD.0000000000020781","Efficacy of integrative Traditional Chinese and Western medicine for the treatment of patients infected with 2019 novel coronavirus (COVID-19): A protocol for systematic review and meta analysis.","No specific anti-virus drugs or vaccines have been available for the treatment of COVID-19. Integrative traditional Chinese and western medicine has been proposed as a therapeutic option with substantial applications in China. This protocol is proposed for a systematic review and meta-analysis that aims to evaluate the efficacy of integrative traditional Chinese and western medicine treatment on patients with COVID-19. Ten databases including PubMed, EMBASE, Cochrane Library, CIHAHL, Web of Scie","2020","07","31","Medicine (Baltimore)","Medicine","Betacoronavirus; Biomarkers; COVID-19; Case-Control Studies; China; Coronavirus Infections; Humans; Medicine, Chinese Traditional; Outcome Assessment, Health Care; Pandemics; Pneumonia, Viral; Quality of Life; Randomized Controlled Trials as Topic; Research Design; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome","Liu","Dan","West China Hospital, Sichuan University, South Renmin Road, Wu Hou District, Chengdu",NA
"18","32702300","10.1016/S0140-6736(20)31611-1","Encouraging results from phase 1/2 COVID-19 vaccine trials.",NA,"2020","08","19","Lancet","Lancet (London, England)","Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Single-Blind Method; Viral Vaccines","Bar-Zeev","Naor","International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21231, USA. Electronic address: nbarzee1@jhu","nbarzee1@jhu.edu"
"19","32702299","10.1016/S0140-6736(20)31605-6","Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.","This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study. This randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China. Healthy adults aged 18 years or older, who were HIV-negative and previous severe acute re","2020","08","24","Lancet","Lancet (London, England)","Adenoviridae; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; China; Coronavirus Infections; Double-Blind Method; Female; Genetic Vectors; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Viral Vaccines; Young Adult","Zhu","Feng-Cai","NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. Electronic address: jszfc@vip.sina","jszfc@vip.sina.com"
"20","32702298","10.1016/S0140-6736(20)31604-4","Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.","The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2. We did a phase 1/2, single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine","2020","08","24","Lancet","Lancet (London, England)","Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Female; Genetic Vectors; Humans; Immunization, Secondary; Immunoglobulin G; Male; Pandemics; Pneumonia, Viral; SARS-CoV-2; Single-Blind Method; Spike Glycoprotein, Coronavirus; T-Lymphocytes; United Kingdom; Viral Vaccines","Folegatti","Pedro M","The Jenner Institute, University of Oxford, Oxford, UK",NA
"21","32701395","10.1377/hlthaff.2020.00646","Designing Pull Funding For A COVID-19 Vaccine.","A widely accessible vaccine is essential to mitigate the health and economic ravages of coronavirus disease 2019 (COVID-19). Without appropriate incentives and coordination, however, firms might not respond at sufficient speed or scale, and competition among countries for limited supply could drive up prices and undercut efficient allocation. Programs relying on &quot;push&quot; incentives (direct cost reimbursement) can be complicated by the funder's inability to observe firms' private cost inf","2020","09","24","Health Aff (Millwood)","Health affairs (Project Hope)","Advance market commitment; COVID-19; Costs and spending; Health policy; Incentives; Manufacturing; Markets; Pandemics; Pharmaceutical innovation; Pharmaceuticals; Prescription drug costs; Research and development; coronavirus; vaccines; COVID-19; Coronavirus Infections; Drug Industry; Female; Financial Management; Global Health; Humans; Male; Marketing of Health Services; Pandemics; Pneumonia, Viral; Viral Vaccines","Snyder","Christopher M","Christopher M. Snyder (chris.snyder@dartmouth.edu) is the Hyatt Professor of Economics, Department of Economics, Dartmouth College, in Hanover, New Hampshire","chris.snyder@dartmouth.edu"
"22","32700555","10.1177/1074248420935740","Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.","In recent months, the new coronavirus SARS-CoV-2 has emerged as a worldwide threat with about 4.2 million confirmed cases and almost 300 000 deaths. Its major clinical presentation is characterized by respiratory symptoms ranging from mild cough to serve pneumonia with fever and potentially even death. Until today, there is no known medication to improve clinical symptoms or even prevent or fight the infection. The search for a useful vaccination is ongoing and it will probably not be available ","2020","11","16","J Cardiovasc Pharmacol Ther","Journal of cardiovascular pharmacology and therapeutics","COVID-19; QT prolongation; arrhythmia; hydroxychloroquine; Arrhythmias, Cardiac; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Retinal Diseases; SARS-CoV-2","Stremmel","Christopher","Medizinische Klinik und Poliklinik I, Klinikum der Universit..t M..nchen, 54187Ludwig-Maximilians University, Munich, Germany",NA
"23","32699860","10.1101/2020.07.13.20152678","Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants.","With the demand for rapid COVID-19 vaccine development and evaluation, this paper aimed to describe the prevalence and correlates of willingness to participate in COVID-19 vaccine trials among university students in China. A cross-sectional survey with 1,912 Chinese university students was conducted during March and April 2020. Bivariate and multivariate analyses were performed to identify variables associated with willingness to participate. The majority of participants (64.01%) indicated willi","2021","04","06","medRxiv","medRxiv : the preprint server for health sciences",NA,"Sun","Shufang","Brown University Alpert Medical School, Department of Psychiatry and Human Behavior",NA
"24","32699167","10.1136/bmjopen-2020-038555","Artificial intelligence mobile health platform for early detection of COVID-19 in quarantine subjects using a wearable biosensor: protocol for a randomised controlled trial.","There is an outbreak of COVID-19 worldwide. As there is no effective therapy or vaccine yet, rigorous implementation of traditional public health measures such as isolation and quarantine remains the most effective tool to control the outbreak. When an asymptomatic individual with COVID-19 exposure is being quarantined, it is necessary to perform temperature and symptom surveillance. As such surveillance is intermittent in nature and highly dependent on self-discipline, it has limited effectiven","2020","07","30","BMJ Open","BMJ open","infection control; telemedicine; virology; Artificial Intelligence; Betacoronavirus; Blood Gas Monitoring, Transcutaneous; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Cloud Computing; Coronavirus Infections; Early Diagnosis; Heart Rate; Hong Kong; Humans; Mobile Applications; Pandemics; Pneumonia, Viral; Quarantine; Respiratory Rate; SARS-CoV-2; Skin Temperature; Smartphone; Telemedicine; Wearable Electronic Devices","Wong","Chun Ka","Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong",NA
"25","32699147","10.1073/pnas.2014154117","Opinion: It's ethical to test promising coronavirus vaccines against less-promising ones.",NA,"2020","08","28","Proc Natl Acad Sci U S A","Proceedings of the National Academy of Sciences of the United States of America","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Viral Vaccines","Eyal","Nir","Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ 08901","nir.eyal@rutgers.edu"
"26","32698494","10.3390/ijms21145130","Self-Amplifying RNA Viruses as RNA Vaccines.","Single-stranded RNA viruses such as alphaviruses, flaviviruses, measles viruses and rhabdoviruses are characterized by their capacity of highly efficient self-amplification of RNA in host cells, which make them attractive vehicles for vaccine development. Particularly, alphaviruses and flaviviruses can be administered as recombinant particles, layered DNA/RNA plasmid vectors carrying the RNA replicon and even RNA replicon molecules. Self-amplifying RNA viral vectors have been used for high level","2020","08","03","Int J Mol Sci","International journal of molecular sciences","RNA replicons; RNA vaccines; RNA vectors; immune responses; protection against pathogens; protection against tumor challenges; Animals; Genetic Vectors; Humans; Mice; Neoplasms; RNA, Viral; Vaccination; Vaccines, Synthetic; Viral Vaccines; Virus Diseases; Viruses","Lundstrom","Kenneth","PanTherapeutics, CH1095 Lutry, Switzerland",NA
"27","32698479","10.3390/ijms21145126","Point-of-Use Rapid Detection of SARS-CoV-2: Nanotechnology-Enabled Solutions for the COVID-19 Pandemic.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the COVID-19 pandemic that has been spreading around the world since December 2019. More than 10 million affected cases and more than half a million deaths have been reported so far, while no vaccine is yet available as a treatment. Considering the global healthcare urgency, several techniques, including whole genome sequencing and computed tomography imaging have been employed for diagnosing infected people. Considerable effort","2020","08","03","Int J Mol Sci","International journal of molecular sciences","COVID-19; SARS-CoV-2; nanoparticles; nanotechnology; point-of-use; rapid detection of virus; Betacoronavirus; COVID-19; Coronavirus Infections; Genome, Viral; Humans; Metal Nanoparticles; Metal-Organic Frameworks; Nanotechnology; Pandemics; Pneumonia, Viral; Point-of-Care Systems; RNA, Viral; SARS-CoV-2; Whole Genome Sequencing","Rabiee","Navid","Department of Chemistry, Sharif University of Technology, Tehran 11155-3516, Iran",NA
"28","32696862","10.1590/1806-9282.66.6.838","Use of remdesivir for patients with Covid-19: a review article.","The etiological agent of COVID-19, which causes severe respiratory diseases such as pneumonia and pulmonary insufficiency, has been confirmed as a new coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is currently no authorized medication for the treatment of COVID-19. No vaccines have been authorized. Thus, this study aimed at conducting a review of the use of Remdesivir in patients with COVID-19. The following electronic databases were used MEDLINE, ","2020","07","28","Rev Assoc Med Bras (1992)","Revista da Associacao Medica Brasileira (1992)","Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2","Azevedo","Thom..s Cavalcanti Pires de","Centro Universit..rio Cesmac, Macei.., AL, Brasil",NA
"29","32694847","10.1038/d41586-020-02154-2","Coronavirus vaccines get a biotech boost.",NA,"2020","07","29","Nature","Nature","Diseases; Immunology; SARS-CoV-2; Vaccines; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Humans; Pandemics; Pneumonia, Viral; Respiratory Syncytial Viruses; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Viral Vaccines","Dance","Amber",NA,NA
"30","32694043","10.1016/j.transci.2020.102875","Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study.","Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infec","2020","12","04","Transfus Apher Sci","Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis","COVID-19; Clinical trial; Convalescent plasma; Hospital stay; Mortality rate; Adult; Aged; Aged, 80 and over; COVID-19; Female; Humans; Immunization, Passive; Male; Middle Aged; SARS-CoV-2; Treatment Outcome; Young Adult","Abolghasemi","Hassan","Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran",NA
"31","32692266","10.1177/2472555220945281","Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.","SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China, in December 2019. Since then, the virus has stretched its grip to almost all the countries in the world, affecting millions of people and causing enormous casualties. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2019. As of June 12, 2020, almost 7.30 million people have already been infected globally, with 413,000 reported casualties. In the United States al","2020","12","07","SLAS Discov","SLAS discovery : advancing life sciences R &amp; D","COVID-19; SARS-CoV-2; monoclonal antibodies; repurposed therapeutics; vaccines; Adenosine Monophosphate; Alanine; Amides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-19; COVID-19 Vaccines; Chloroquine; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Lactams; Mice, Transgenic; Pyrazines; SARS-CoV-2; Small Molecule Libraries; Sulfonamides; Vaccines, Synthetic","Banday","Abid H","Department of Chemistry and Biochemistry, Auburn University, Auburn, Alabama, USA",NA
"32","32688370","10.1038/s41390-020-1067-3","Inclusion of children and pregnant women in COVID-19 intervention trials.",NA,"2021","05","25","Pediatr Res","Pediatric research","Adult; Age Factors; COVID-19; COVID-19 Vaccines; Child; Clinical Trials as Topic; Female; Humans; Informed Consent; Patient Selection; Pregnancy; Pregnancy Complications, Infectious; Research Design; SARS-CoV-2","Malhotra","Atul","Monash Newborn, Monash Children's Hospital, Melbourne, VIC, Australia. atul.malhotra@monash","atul.malhotra@monash.edu"
"33","32687112","10.4103/npmj.npmj_157_20","COVID-19 pandemic: A global health burden.","Coronavirus disease 2019 (COVID-19) pandemic began in China with a group of severe pneumonia cases, later identified to be caused by the severe acute respiratory syndrome coronavirus 2 in December 2019. Thailand reported the first COVID-19 case outside of China on 13<sup>th</sup> January 2020, Africa reported its first case in Egypt on 14<sup>th</sup> February 2020 and Nigeria reported its index case of COVID-19 on 27<sup>th</sup> February 2020. Virtually, all countries in the world are affected","2020","07","23","Niger Postgrad Med J","The Nigerian postgraduate medical journal","Coronavirus disease 2019; Nigeria; health burden; pandemic; Betacoronavirus; COVID-19; Coronavirus; Coronavirus Infections; Cost of Illness; Disease Outbreaks; Global Health; Humans; Nigeria; Pandemics; Pneumonia, Viral; SARS-CoV-2","Akande","Oluwatosin Wuraola","Department of Epidemiology and Community Health, University of Ilorin Teaching Hospital, Ilorin, Kwara State, Nigeria",NA
"34","32671831","10.1111/cei.13495","COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases.","Although most autoimmune diseases are considered to be CD4 T cell- or antibody-mediated, many respond to CD20-depleting antibodies that have limited influence on CD4 and plasma cells. This includes rituximab, oblinutuzumab and ofatumumab that are used in cancer, rheumatoid arthritis and off-label in a large number of other autoimmunities and ocrelizumab in multiple sclerosis. Recently, the COVID-19 pandemic created concerns about immunosuppression in autoimmunity, leading to cessation or a delay","2020","11","13","Clin Exp Immunol","Clinical and experimental immunology","B cell; CD20; COVID-19; autoimmunity; immunotherapy; multiple sclerosis; ocrelizumab; rheumatoid arthritis; rituximab; Animals; Antibodies, Monoclonal; Antigens, CD20; Autoimmune Diseases; B-Lymphocytes; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Lymphocyte Depletion; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vaccination; Viral Vaccines","Baker","D","Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK",NA
"35","32669462","10.1128/mSphere.00669-20","Human Infection Challenge Studies: a Test for the Social Value Criterion of Research Ethics.","Human infection challenge studies involving the intentional infection of research participants with a disease-causing agent have recently been suggested as a means to speed up the search for a vaccine for the ongoing coronavirus disease 2019 (COVID-19) outbreak. Calls for challenge studies, however, rely on the expected social value of these studies. This value represents more than the simple possibility that a successful study will lead to the rapid development and dissemination of vaccines but","2020","07","27","mSphere","mSphere","COVID-19; challenge studies; coronavirus; global health; research ethics; Betacoronavirus; Biomedical Research; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Ethics, Research; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Social Values; Viral Vaccines","Evans","Nicholas G","Department of Philosophy, University of Massachusetts Lowell, Lowell, Massachusetts, USA Nicholas_evans@uml","evans@uml.edu"
"36","32667492","10.6061/clinics/2020/e2124","Trained innate immunity, COVID-19 therapeutic dilemma, and fake science.",NA,"2020","07","21","Clinics (Sao Paulo)","Clinics (Sao Paulo, Brazil)","BCG Vaccine; Betacoronavirus; COVID-19; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunity, Innate; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vaccination","Beliz..rio","Jos.. Ernesto","Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR",NA
"37","32667191","10.1021/acsnano.0c04117","Hard Nanomaterials in Time of Viral Pandemics.","The SARS-Cov-2 pandemic has spread worldwide during 2020, setting up an uncertain start of this decade. The measures to contain infection taken by many governments have been extremely severe by imposing home lockdown and industrial production shutdown, making this the biggest crisis since the second world war. Additionally, the continuous colonization of wild natural lands may touch unknown virus reservoirs, causing the spread of epidemics. Apart from SARS-Cov-2, the recent history has seen the ","2020","09","14","ACS Nano","ACS nano","antiviral; biomaterials; immune system; nanoparticles; phototherapy; surface chemistry; vaccine; virucidal; Adaptive Immunity; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus Infections; Drug Delivery Systems; Fullerenes; Host Microbial Interactions; Humans; Immunity, Innate; Metal Nanoparticles; Models, Biological; Nanostructures; Nanotechnology; Pandemics; Pneumonia, Viral; Reactive Oxygen Species; SARS-CoV-2; Virus Internalization","Reina","Giacomo","CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg ISIS, 67000 Strasbourg, France",NA
"38","32664543","10.3390/ijms21144903","Lactoferrin as Protective Natural Barrier of Respiratory and Intestinal Mucosa against Coronavirus Infection and Inflammation.","Recently, the world has been dealing with a devastating global pandemic coronavirus infection, with more than 12 million infected worldwide and over 300,000 deaths as of May 15th 2020, related to a novel coronavirus (2019-nCoV), characterized by a spherical morphology and identified through next-generation sequencing. Although the respiratory tract is the primary portal of entry of SARS-CoV-2, gastrointestinal involvement associated with nausea, vomiting and diarrhoea may also occur. No drug or ","2020","07","24","Int J Mol Sci","International journal of molecular sciences","SARS; coronavirus; lactoferrin; Angiotensin-Converting Enzyme 2; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Inflammation; Intestinal Mucosa; Iron; Lactoferrin; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Respiratory Mucosa; SARS-CoV-2; Virus Internalization","Campione","Elena","Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy",NA
"39","32663912","10.1056/NEJMoa2022483","An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein. We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 ..g, 100 ..g, or 250 ..g. There were 15 p","2020","11","16","N Engl J Med","The New England journal of medicine","Adult; Antibodies, Neutralizing; Antibodies, Viral; Antibody Formation; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Female; Humans; Immunization, Secondary; Male; Pandemics; Pneumonia, Viral; RNA, Messenger; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Viral Vaccines; Young Adult","Jackson","Lisa A","From Kaiser Permanente Washington Health Research Institute (L.A.J.) and the Center for Global Infectious Disease Research (CGIDR), Seattle Children's Research Institute (R.N.C.) - both in Seattle",NA
"40","32662677","10.1080/17460441.2020.1791076","The combination of artificial intelligence and systems biology for intelligent vaccine design.","A new body of evidence depicts the applications of artificial intelligence and systems biology in vaccine design and development. The combination of both approaches shall revolutionize healthcare, accelerating clinical trial processes and reducing the costs and time involved in drug research and development. This review explores the basics of artificial intelligence and systems biology approaches in the vaccine development pipeline. The topics include a detailed description of epitope prediction","2020","11","05","Expert Opin Drug Discov","Expert opinion on drug discovery","Covid-19; Vaccine development; agent-based models; artificial intelligence; epitope prediction; immune system modeling; systems biology; Artificial Intelligence; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Drug Development; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Systems Biology; Viral Vaccines","Russo","Giulia","Department of Drug Sciences, University of Catania , Catania, Italy",NA
"41","32661140","10.1128/JVI.01279-20","The SARS-CoV-2 N Protein Is a Good Component in a Vaccine.",NA,"2020","09","03","J Virol","Journal of virology","COVID-19; DNA vaccine; SARS-CoV-2; vaccine; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Nucleocapsid Proteins; Pandemics; Pneumonia, Viral; SARS-CoV-2","Ahl..n","Gustaf","Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet, Stockholm, Sweden",NA
"42","32661074","10.1136/medethics-2020-106501","Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines.","To counter the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), some have proposed accelerating SARS-CoV-2 vaccine development through controlled human infection (or 'challenge') trials. These trials would involve the deliberate exposure of relatively few young, healthy volunteers to SARS-CoV-2. We defend this proposal against the charge that there is still too much uncertainty surrounding the risks of COVID-19 to responsibly run such a trial.","2020","12","23","J Med Ethics","Journal of medical ethics","clinical trials; ethics; philosophical ethics; research ethics; Biomedical Research; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Healthy Volunteers; Humans; Informed Consent; Pandemics; Risk Factors; SARS-CoV-2; Safety","Steel","Robert","Center for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, New Jersey, USA",NA
"43","32658877","10.1701/3407.33920","[The naked king in the pandemic: about the production and communication of scientific knowledge at the time of SARS-CoV-2.]","The SARS-CoV-2 pandemic has lifted the veil about how medical knowledge is produced and disseminated. Action Bias, together with economic, academic and media-related interests, has concurred to generate and spread low-value and even unreliable information about some hypothetical therapeutic interventions for CoViD-19. Not only this &quot;infodemic&quot; has weakened people's ability to make informed health choices, but it also has influenced the process of new evidence generation through the vio","2020","07","24","Recenti Prog Med","Recenti progressi in medicina","Antiviral Agents; Betacoronavirus; COVID-19; Communication; Coronavirus Infections; Decision Making; Drug Repositioning; Evidence-Based Medicine; Health Services Needs and Demand; Humans; Information Dissemination; Information Seeking Behavior; Off-Label Use; Pandemics; Patient Education as Topic; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Therapeutic Equipoise; Viral Vaccines","Alderighi","Camilla","Ordine dei Medici Chirurghi e degli Odontoiatri della Provincia di Firenze",NA
"44","32658841","","Development of a hyperimmune equine serum therapy for COVID-19 in Argentina.","The disease named COVID-19, caused by the SARS-CoV-2 coronavirus, is currently generating a global pandemic. Vaccine development is no doubt the best long-term immunological approach, but in the current epidemiologic and health emergency there is a need for rapid and effective solutions. Convalescent plasma is the only antibody-based therapy available for COVID-19 patients to date. Equine polyclonal antibodies (EpAbs) put forward a sound alternative. The new generation of processed and purified ","2020","08","07","Medicina (B Aires)","Medicina","Argentina; COVID-19; F(ab')2 fragments; hyperimmune horse sera; Animals; Antibodies, Viral; Argentina; Betacoronavirus; COVID-19; Coronavirus Infections; Horses; Humans; Immune Sera; Immunization, Passive; Immunoglobulin Fab Fragments; Immunoglobulin G; Neutralization Tests; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus","Zylberman","Vanesa","Inmunova S.A., San Mart..n, Provincia de Buenos Aires, Argentina",NA
"45","32653662","10.1016/j.cmi.2020.07.008","Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2.","Asymptomatic patients, together with those with mild symptoms of coronavirus disease 2019 (COVID-19), may play an important role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. However, the dynamics of virus shedding during the various phases of the clinical course of COVID-19 remains unclear at this stage. A total of 18 patients found to be positive for SARS-CoV-2 infection by real-time reverse transcription PCR (RT-PCR) assay and admitted to Chongqing University C","2020","11","20","Clin Microbiol Infect","Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","Antibodies; Asymptomatic infections; Convalescence; SARS-CoV-2; Virus shedding; Adult; Antibodies, Viral; Asymptomatic Infections; Betacoronavirus; COVID-19; COVID-19 Testing; COVID-19 Vaccines; China; Clinical Laboratory Techniques; Convalescence; Coronavirus Infections; Female; Hospitalization; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; RNA, Viral; SARS-CoV-2; Virus Shedding","Li","W","Chongqing University Central Hospital, China",NA
"46","32653511","10.1016/j.freeradbiomed.2020.07.005","Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.","Studies have shown that infection, excessive coagulation, cytokine storm, leukopenia, lymphopenia, hypoxemia and oxidative stress have also been observed in critically ill Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) patients in addition to the onset symptoms. There are still no approved drugs or vaccines. Dietary supplements could possibly improve the patient's recovery. Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), present an anti","2020","08","27","Free Radic Biol Med","Free radical biology &amp; medicine","DHA; EPA; Inflammation; Oxidative stress; SARS-CoV-2; SPMs; Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; COVID-19; Coronavirus Infections; Cytokine Release Syndrome; Dietary Supplements; Disseminated Intravascular Coagulation; Docosahexaenoic Acids; Eicosapentaenoic Acid; Humans; Hypoxia; Leukopenia; Oxidative Stress; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Reactive Oxygen Species; SARS-CoV-2","Rogero","Marcelo M","Nutritional Genomics and Inflammation Laboratory, Department of Nutrition, School of Public Health, University of S..o Paulo, 01246-904, S..o Paulo, Brazil",NA
"47","32653463","10.1016/j.prrv.2020.06.010","Vaccines for COVID-19: The current state of play.","There is a strong consensus globally that a COVID-19 vaccine is likely the most effective approach to sustainably controlling the COVID-19 pandemic. An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials. Here, we review vaccine types, and progress with 10 vaccine candidates against SARS-CoV-2 - the virus that causes COVID-19 - currently undergoing early phase human trials. We also consider the many challenges o","2020","09","04","Paediatr Respir Rev","Paediatric respiratory reviews","Covid 19; Human trials; Timeline; Vaccines; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Humans; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; SARS Virus; SARS-CoV-2; Vaccines, DNA; Vaccines, Synthetic; Viral Vaccines","Koirala","Archana","National Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia","Archana.Koirala@health.nsw.gov.au"
"48","32653224","10.1016/j.aller.2020.05.002","BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?","The impact of COVID-19 is changing with country wise and depend on universal immunization policies. COVID-19 badly affects countries that did not have universal immunization policies or having them only for the selective population of countries (highly prominent population) like Italy, USA, UK, Netherland, etc. Universal immunization of BCG can provide great protection against the COVID-19 infection because the BCG vaccine gives broad protection against respiratory infections. BCG vaccine induce","2020","10","05","Allergol Immunopathol (Madr)","Allergologia et immunopathologia","Antigen specific immunity; BCG; COVID-19; HCW; Immune response; Revaccination; Adaptive Immunity; BCG Vaccine; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunization, Secondary; Mass Vaccination; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Sharma","A R","Post Graduate Institute for Medical Education and Research (PGIMER), Chandigarh, India",NA
"49","32653040","10.1186/s12931-020-01439-4","The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19.","Bacillus Calmette-Gu..rin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conduc","2020","07","21","Respir Res","Respiratory research","BCG Vaccine; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Cost-Benefit Analysis; Female; Humans; Male; Needs Assessment; Pandemics; Pneumonia, Viral; Poverty; Primary Prevention; Quality Control; Role; Socioeconomic Factors; Survival Analysis; Vaccination","Pereira","Marcos","Institute of Collective Health, Federal University of Bahia, Salvador, Brazil. pereira.santosm@yahoo","pereira.santosm@yahoo.com"
"50","32650672","10.1177/1740774520939871","Clinical trials in the time of a pandemic.","The first rumblings about a new coronavirus spreading in China were heard in January 2020. By the end of that month, the World Health Organization, recognizing the severity of the disease and the potential for global spread, had declared a public health emergency. By February 2020, cases had been identified in multiple countries, clinical trials of treatments with some biological plausibility had begun in China, and the initial steps of vaccine development were underway. In mid-March, by which t","2020","10","15","Clin Trials","Clinical trials (London, England)","COVID-19; Clinical trials; pandemic; treatment; vaccines; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Disease Transmission, Infectious; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2","Ellenberg","Susan S","Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA",NA
"51","32650355","10.15586/jptcp.v27iSP1.689","Antirheumatic drugs for COVID-19 treatment based on the phases of the disease: Current concept.","COVID-19 disease is the most recent pandemic, since it has affected more than four and a half million people and caused more than 300,000 deaths. It is a very complex systemic disease in terms of pathogenesis, treatment, and prognosis. Pharmacological treatment may include antiviral and antimalarial drugs, antibiotics, monoclonal antibodies, corticosteroids as well as low-molecular-weight heparins to prevent the evolution of the disease from reaching the severe inflammatory phase that can lead t","2020","07","20","J Popul Ther Clin Pharmacol","Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique","COVID-19; antirheumatic drugs; phases; treatment; Antibodies, Monoclonal; Antimalarials; Antirheumatic Agents; COVID-19; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral","Valentini","Marco","Rheumatology Unit, San Pier Damiano Hospital, Faenza (RA), Italy",NA
"52","32649315","10.1097/PAP.0000000000000274","Autopsy Services and Emergency Preparedness of a Tertiary Academic Hospital Mortuary for the COVID-19 Public Health Emergency: The Yale Plan.","Pathology Autopsy and Mortuary Services have been front and center in the severe acute respiratory syndrome coronavirus 2 (SARS-Co-V-2) pandemic. The sheer number of fatalities from the pandemic have been unlike any other in recent memory and needed the rapid creation of new protocols and paradigms to manage the situation. This required rapidly escalating mortuary capacity to manage the increased fatalities from the pandemic with the establishment of lines of communication and networking with go","2020","10","15","Adv Anat Pathol","Advances in anatomic pathology","Autopsy; Betacoronavirus; COVID-19; Coronavirus Infections; Emergencies; Humans; Mortuary Practice; Occupational Exposure; Occupational Health; Pandemics; Pathology, Clinical; Pneumonia, Viral; Public Health; SARS-CoV-2","McGuone","Declan","Department of Pathology, Yale Medical School, New Haven",NA
"53","32648899","10.1001/jama.2020.12839","Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.","The coronavirus disease 2019 (COVID-19) pandemic, due to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a worldwide sudden and substantial increase in hospitalizations for pneumonia with multiorgan disease. This review discusses current evidence regarding the pathophysiology, transmission, diagnosis, and management of COVID-19. SARS-CoV-2 is spread primarily via respiratory droplets during close face-to-face contact. Infection can be spread by asymptomatic, pr","2020","10","01","JAMA","JAMA","Betacoronavirus; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Coronavirus Infections; Global Health; Health Status Disparities; Hospital Mortality; Humans; Lung; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Viral Vaccines","Wiersinga","W Joost","Division of Infectious Diseases, Department of Medicine, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, the Netherlands",NA
"54","32646869","10.1503/cmaj.201237","Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.",NA,"2020","09","02","CMAJ","CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","Betacoronavirus; COVID-19; COVID-19 Vaccines; Communicable Disease Control; Coronavirus Infections; Drug Development; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Abu-Raya","Bahaa","Vaccine Evaluation Center, BC Children's Hospital Research Institute, and Division of Infectious Diseases, Department of Pediatrics, University of British Columbia, Vancouver, BC baburaya@bcchr.ubc","baburaya@bcchr.ubc.ca"
"55","32645630","10.1016/j.intimp.2020.106740","Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.","There is no vaccine or specific antiviral treatment for HCoVs infection. The use of type I interferons for coronavirus is still under great debate in clinical practice. A literature search of all relevant studies published on PubMed, Cochrane library, Web of Science database, Science Direct, Wanfang Data, and China National Knowledge Infrastructure (CNKI) until February 2020 was performed. Of the 1081 identified articles, only 15 studies were included in the final analysis. Comorbidities and del","2020","08","24","Int Immunopharmacol","International immunopharmacology","Human coronavirus; MERS-CoV; SARS-CoV; SARS-CoV-2; Type I interferons; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Interferon Type I; Middle East Respiratory Syndrome Coronavirus; Observational Studies as Topic; Pandemics; Pneumonia, Viral; SARS Virus; SARS-CoV-2; Severe Acute Respiratory Syndrome; Survival Analysis; Treatment Outcome","Yu","Chengjun","Children's Hospital of Chongqing Medical University, Chongqing, China",NA
"56","32643436","10.1080/1061186X.2020.1793990","Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19.","A global outbreak of the SARS-CoV-2 virus has infected millions of people over a short period of time. The communicability and increased mortality from the SARS-CoV-2 infection mandated the WHO to declare COVID-19 a worldwide pandemic. The virus outbreak has spread when there are no approved vaccines, treatments, or prophylactic therapies available. Researchers from all over the world have prioritised development of vaccines and antivirals. Several vaccine projects have seen successes in preclin","2020","09","07","J Drug Target","Journal of drug targeting","COVID-19; SARS-CoV-2; antiviral; contact tracing; convalescent plasma; pandemic; personal protective equipment; social distancing; vaccine; ventilator support; Animals; Antiviral Agents; COVID-19; Coronavirus Infections; Humans; Pandemics; Personal Protective Equipment; Pneumonia, Viral; Respiration, Artificial; Social Isolation","Alvi","Mohammed M","Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA, USA",NA
"57","32638362","10.1002/ijc.33189","The European response to the WHO call to eliminate cervical cancer as a public health problem.","The age-standardised incidence of cervical cancer in Europe varies widely by country (between 3 and 25/100000 women-years) in 2018. Human papillomavirus (HPV) vaccine coverage is low in countries with the highest incidence and screening performance is heterogeneous among European countries. A broad group of delegates of scientific professional societies and cancer organisations endorse the principles of the WHO call to eliminate cervical cancer as a public health problem, also in Europe. All Eur","2020","12","28","Int J Cancer","International journal of cancer","COVID-19; Europe; HPV vaccination; WHO; cervical cancer screening; elimination of cervical cancer; Adolescent; Adult; Alphapapillomavirus; COVID-19; Early Detection of Cancer; Europe; Female; Humans; Male; Middle Aged; Pandemics; Papillomavirus Infections; Papillomavirus Vaccines; Public Health; SARS-CoV-2; Uterine Cervical Neoplasms; Vaccination; World Health Organization; Young Adult","Arbyn","Marc","Coordinator Unit Cancer Epidemiology, Belgian Cancer Centre, Sciensano, Brussels, Belgium",NA
"58","32636754","10.3389/fphar.2020.00937","A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic.","A novel coronavirus SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) has entered the human population and has spread rapidly around the world in the first half of 2020 causing a global pandemic. The virus uses its spike glycoprotein receptor-binding domain to interact with host cell angiotensin-converting enzyme 2 (ACE2) sites to initiate a cascade of events that culminate in severe acute respiratory syndrome in some individuals. In efforts to curtail viral spread, authorities initiated fa","2020","09","28","Front Pharmacol","Frontiers in pharmacology","COVID-19; SARS-CoV-2; clinical trial; coronavirus; immune response; public health; vaccine","Funk","Colin D","Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada",NA
"59","32636542","","Laboratory Tests for COVID-19: A Review of Peer-Reviewed Publications and Implications for Clinical Use.","Diagnostic tests for the coronavirus infection 2019 (COVID-19) are critical for prompt diagnosis, treatment and isolation to break the cycle of transmission. A positive real-time reverse-transcriptase polymerase chain reaction (RT-PCR), in conjunction with clinical and epidemiologic data, is the current standard for diagnosis, but several challenges still exist. Serological assays help to understand epidemiology better and to evaluate vaccine responses but they are unreliable for diagnosis in th","2020","07","13","Mo Med","Missouri medicine","Betacoronavirus; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Coronavirus Infections; Humans; Molecular Diagnostic Techniques; Pandemics; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2","Shyu","Daniel","Department of Medicine, University of Missouri - Columbia, Columbia, Missouri",NA
"60","32632960","10.1002/ddr.21709","Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.","Coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is one of the most contagious diseases in human history that has already affected millions of lives worldwide. To date, no vaccines or effective therapeutics have been discovered yet that may successfully treat COVID-19 patients or contain the transmission of the virus. Scientific communities across the globe responded rapidly and have been working relentlessly to develop drugs and vaccines","2020","09","09","Drug Dev Res","Drug development research","COVID-19; clinical trial; drug repurposing; drug targets; therapeutics; vaccines","Sohag","Abdullah Al Mamun","Department of Biochemistry and Molecular Biology, Bangladesh Agricultural University, Mymensingh, 2202, Bangladesh",NA
"61","32628748","10.1093/cid/ciaa935","Evaluating Use Cases for Human Challenge Trials in Accelerating SARS-CoV-2 Vaccine Development.","Human challenge trials (HCTs) have been proposed as a means to accelerate SARS-CoV-2 vaccine development. We identify and discuss 3 potential use cases of HCTs in the current pandemic: evaluating efficacy, converging on correlates of protection, and improving understanding of pathogenesis and the human immune response. We outline the limitations of HCTs and find that HCTs are likely to be most useful for vaccine candidates currently in preclinical stages of development. We conclude that, while c","2021","02","18","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","COVID-19; controlled human infection; human challenge trial; pandemic; vaccine evaluation; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Pandemics; SARS-CoV-2","Nguyen","Linh Chi","Department of Politics and International Relations, University of Oxford, Oxford, United Kingdom",NA
"62","32625198","10.3389/fmicb.2020.01476","Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?","Malaria remains a major global health burden, killing hundreds of thousands annually, especially in sub-Saharan Africa. In 2019, a Phase IV Expanded Programme on Immunization (EPI)-linked malaria vaccine implementation was underway. However, in December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with many clinical, epidemiological, and biological parallels to malaria, was reported in Wuhan,","2020","09","28","Front Microbiol","Frontiers in microbiology","ACE2; COVID-19; SARS-CoV-2; coronaviruses; malaria; plasmodium","Nghochuzie","Nora Nganyewo","West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Accra, Ghana",NA
"63","32624257","10.1016/j.jaci.2020.05.033","Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.","The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help ","2020","08","25","J Allergy Clin Immunol","The Journal of allergy and clinical immunology","ACE2; COVID-19; TMPRSS2; allergic rhinitis; asthma; receptor-binding domain; severe acute respiratory syndrome coronavirus 2; Adenosine Monophosphate; Age Factors; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Asthma; Betacoronavirus; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Clinical Trials as Topic; Coronavirus Infections; Drug Repositioning; Humans; Masks; Pandemics; Peptidyl-Dipeptidase A; Physical Distancing; Pneumonia, Viral; Prevalence; Quarantine; Receptors, Virus; SARS-CoV-2; Severity of Illness Index; Spike Glycoprotein, Coronavirus","Hosoki","Koa","Department of Medicine, Immunology Allergy and Rheumatology, Baylor College of Medicine, Houston, Tex",NA
"64","32623082","10.1016/j.ijid.2020.06.099","Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.","The United States is in an acceleration phase of the COVID-19 pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies. The purpose of this study was to evaluate the role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19. Multi-center retrospective observational study. The Henry Ford Health System (HFHS) in Southeast Michigan: la","2020","07","30","Int J Infect Dis","International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","COVID-19; Coronavirus; Hydroxychloroquine; Mortality; SARS-COV-2; Therapy; Aged; Azithromycin; Betacoronavirus; COVID-19; Coronavirus Infections; Drug Therapy, Combination; Female; Hospital Mortality; Hospitalization; Humans; Hydroxychloroquine; Inpatients; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Risk Factors; SARS-CoV-2","Arshad","Samia","Infectious Diseases, Henry Ford Hospital, Detroit, MI, United States",NA
"65","32622723","10.1016/j.phrs.2020.105056","Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis.","Currently, coronavirus disease 2019 (COVID-19), which can lead to severe respiratory failure and death, is now a global pandemic with no specific anti-viral drugs or vaccines. However, It is worth noting that traditional Chinese medicine (TCM), especially Chinese herbal medicine (CHM), has been widely applied in mainland China since outbreak, bringing new hope for the prevention and control of COVID-19. A comprehensive literature searching was conducted in 7 electronic databases from their incep","2020","11","25","Pharmacol Res","Pharmacological research","Chinese herbal medicine; Coronavirus disease 2019; Meta-analysis; Randomized controlled trial; Systematic review; Traditional Chinese medicine; COVID-19; Coronavirus Infections; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic","Xiong","Xingjiang","Department of Cardiovascular Care Unit, Guang'Anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Electronic address: xiongxingjiangtcm@163","xiongxingjiangtcm@163.com"
"66","32620409","10.1016/j.transci.2020.102867","Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia.","Convalescent Plasma (CP) therapy is of interest as no vaccine or specific treatment is available for emerging viruses such as severe acute respiratory syndrome coronavirus 2 causing Covid-19. It was aimed to report the results of our patients who underwent CP in the treatment of Covid-19. CP treatment was applied to 26 Covid-19 patients in intensive care unit who had quantitative reverse transcriptase-polymerase chain reaction positive Sars-Cov-2 infection. Plasma was collected at least 14 days ","2020","12","04","Transfus Apher Sci","Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis","Convalescent plasma; Coronavirus; Covid-19; Immun plasma; Sars-Cov-2 infection; Aged; COVID-19; Female; Humans; Immunization, Passive; Male; Turkey","Erkurt","Mehmet Ali","Inonu University, Turgut Ozal Medical Center, Adult Hematology Department, Malatya, Turkey. Electronic address: erkurtali@hotmail","erkurtali@hotmail.com"
"67","32615862","10.1080/22221751.2020.1791736","Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.","The COVID-19 pandemic has caused a global public health crisis. There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the COVID-19 pandemic. The Chinese scientists supported by private and government resources have adopted extensive efforts to identify effective drugs against the virus. To date, a large number of clinical trials addressing various aspects of COVID19 have been registered in the Chinese Clinical Trial Registry (C","2020","08","04","Emerg Microbes Infect","Emerging microbes &amp; infections","COVID-19; Traditional Chinese Medicine; anti-viral drug; clinical trials; vaccine; Antiviral Agents; Betacoronavirus; COVID-19; China; Clinical Trials as Topic; Coronavirus Infections; Humans; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Registries; Research Design; SARS-CoV-2","Xu","Peng","Neurology Department, The A...liated Hospital to Changchun University of Chinese Medicine, Changchun, People's Republic of China",NA
"68","32610334","10.1159/000508991","COVID-19 Infection and Neurological Complications: Present Findings and Future Predictions.","The present outbreak caused by SARS-CoV-2, an influenza virus with neurotropic potential, presents with neurological manifestations in a large proportion of the affected individuals. Disorders of the central and peripheral nervous system are all present, while stroke, ataxia, seizures, and depressed level of consciousness are more common in severely affected patients. People with these severe complications are most likely elderly with medical comorbidities, especially hypertension and other vasc","2020","10","28","Neuroepidemiology","Neuroepidemiology","Coronavirus; Infection; Neurological disorders; Outbreak; Betacoronavirus; COVID-19; Coronavirus Infections; Forecasting; Humans; Nervous System Diseases; Pandemics; Pneumonia, Viral; SARS-CoV-2","Beghi","Ettore","Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy, ettore.beghi@marionegri","ettore.beghi@marionegri.it"
"69","32607526","10.1101/2020.06.26.20141044","Cost Benefit Analysis of Limited Reopening Relative to a Herd Immunity Strategy or Shelter in Place for SARS-CoV-2 in the United States.","Fierce debate about the health and financial tradeoffs presented by different COVID-19 pandemic mitigation strategies highlights the need for rigorous quantitative evaluation of policy options. To quantify the economic value of the costs and benefits of a policy of continued limited reopening with social distancing relative to alternative COVID-19 response strategies in the United States. We estimate the number and value of quality-adjusted life-years (QALY) gained from mortality averted, with a","2020","09","28","medRxiv","medRxiv : the preprint server for health sciences",NA,"Schonberger","Robert B",NA,NA
"70","32607505","10.33696/Signaling.1.006","COVID-19 Clinical Research.","While the global COVID-19 pandemic has challenged the entire humanity and health systems, it also triggered researchers to urgently perform clinical trials to assess the safety and efficacy of many agents and modalities to combat COVID-19. As of April 22, over 650 clinical studies have been registered both in USA and internationally. Results from these studies are also coming at a brisk pace in this unprecedented emergency. We searched the NCI website and Medline and summarize various national a","2020","09","28","J Cell Signal","Journal of cellular signaling","BCG; COVID-19; Convalescent plasma; Cytokine storm; Immunomodulatory; Immunosuppression; SARS-CoV-2; Vaccines","Chi","Jeffrey","Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra, Feinstein Institute for Medical Research, Lake Success, NY, USA",NA
"71","32605278","10.3390/jcm9072030","Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19.","Hospital admissions and mortality from the Coronavirus disease 2019 (COVID-19) pandemic are spreading throughout the world, and second and third waves are thought to be likely. Risk factors for severe COVID-19 include diabetes, chronic kidney disease and cardiovascular disease. Currently, there is no vaccine and no approved therapy. Therapeutic approaches are aimed at preventing viral replication and spread, limiting the impact of the inflammatory overdrive (cytokine storm), preventing thromboem","2020","09","28","J Clin Med","Journal of clinical medicine","COVID-19; SGLT2; canagliflozin; cardiovascular; chronic kidney disease; dapagliflozin; diabetes; empagliflozin","Fernandez-Fernandez","Beatriz","IIS-Fundaci..n Jim..nez Diaz, Department of Medicine, School of Medicine, Universidad Aut..noma de Madrid, 28029 Madrid, Spain",NA
"72","32604775","10.3390/medicina56060315","A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era.","Background and objective: Despite medical advances, we are facing the unprecedented disaster of the coronavirus disease 2019 (COVID-19) pandemic without available treatments and effective vaccines. As the COVID-19 pandemic has approached its culmination, desperate efforts have been made to seek proper treatments and response strategies, and the number of clinical trials has been rapidly increasing. In this time of the pandemic, it is believed that learning lessons from it would be meaning","2020","07","07","Medicina (Kaunas)","Medicina (Kaunas, Lithuania)","COVID-19; clinical trials; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Databases, Factual; Humans; Pandemics; Pneumonia, Viral","Lee","Jinhee","Department of Psychiatry, Yonsei University, Wonju College of Medicine, Wonju Kangwon 26426, Korea",NA
"73","32601655","10.17061/phrp3022010","Enhancing global health communication during a crisis: lessons from the COVID-19 pandemic.","The understanding and practice of public health crisis communication are improved through the study of responses to past crises, but require retooling for present challenges. The 'Addressing Ebola and other outbreaks' checklist contains guiding principles built upon maxims developed from a World Health Organization consultation in response to the mad cow (bovine spongiform encephalopathy) crisis that were later adopted for Ebola. The purpose of this article is to adapt the checklist for the heal","2020","07","06","Public Health Res Pract","Public health research &amp; practice","Betacoronavirus; COVID-19; Coronavirus Infections; Global Health; Health Communication; Health Literacy; Health Promotion; Humans; Information Dissemination; Pandemics; Pneumonia, Viral; SARS-CoV-2; Social Media","Ratzan","Scott C","CUNY Graduate School of Public Health and Health Policy, City University of New York, US","sratzan@aol.com"
"74","32600908","10.1016/j.vaccine.2020.06.022","Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.","The World Health Organization declared the COVID-19 disease as a pandemic requiring a rapid response. Through online search, direct communication with network members and an internal survey, engagements of developing countries' vaccine manufacturers' network members in the research and development of COVID-19 vaccines and their capacities in the manufacturing, fill-finish and distribution of vaccines were assessed. Currently, 19 network members engaged in research and development of COVID-19 vac","2020","07","20","Vaccine","Vaccine","Biomedical Research; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Industry; Humans; International Cooperation; Pandemics; Pneumonia, Viral; Viral Vaccines; World Health Organization","Pagliusi","Sonia","DCVMN International, Route de Crassier 7, 1262 Eysins-Nyon, Switzerland. Electronic address: s.pagliusi@dcvmn","s.pagliusi@dcvmn.net"
"75","32592501","10.1002/jmv.26232","The cytokine storm and COVID-19.","Coronavirus disease 2019 (COVID-19), which began in Wuhan, China, in December 2019, has caused a large global pandemic and poses a serious threat to public health. More than 4 million cases of COVID-19, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been confirmed as of 11 May 2020. SARS-CoV-2 is a highly pathogenic and transmissible coronavirus that primarily spreads through respiratory droplets and close contact. A growing body of clinical data sugges","2021","03","02","J Med Virol","Journal of medical virology","COVID-19; SARS-CoV-2; cytokine storm; literature review; COVID-19; Clinical Trials as Topic; Cytokine Release Syndrome; Humans; Lung; Severity of Illness Index","Hu","Biying","The First Clinical Medical College of Jinan University, The First Affiliated Hospital of Jinan University, Guangzhou, China",NA
"76","32591957","10.1007/s10198-020-01208-6","Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19.",NA,"2020","08","20","Eur J Health Econ","The European journal of health economics : HEPAC : health economics in prevention and care","Adolescent; Adult; Aged; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Design; Europe; Female; Humans; Immunity, Herd; Male; Middle Aged; Pandemics; Patient Acceptance of Health Care; Pneumonia, Viral; SARS-CoV-2; Surveys and Questionnaires; Viral Vaccines; World Health Organization","Neumann-B..hme","Sebastian","Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. neumann@eshpm.eur","neumann@eshpm.eur.nl"
"77","32584199","10.1080/20469047.2020.1781356","Human and novel coronavirus infections in children: a review.","Coronaviruses, seven of which are known to infect humans, can cause a spectrum of clinical presentations ranging from asymptomatic infection to severe illness and death. Four human coronaviruses (hCoVs)-229E, HKU1, NL63 and OC43-circulate globally, commonly infect children and typically cause mild upper respiratory tract infections. Three novel coronaviruses of zoonotic origin have emerged during the past two decades: severe acute respiratory syndrome coronavirus (SARS-CoV-1), Middle East respir","2021","04","27","Paediatr Int Child Health","Paediatrics and international child health","2019-nCoV; Coronavirus; MERS-CoV; Middle East respiratory syndrome (MERS); SARS-CoV-1; SARS-CoV-2; coronavirus disease 2019 (COVID-19); novel coronavirus; severe acute respiratory syndrome (SARS); Adolescent; COVID-19; COVID-19 Vaccines; Child; Child, Preschool; Coronavirus Infections; Disease Outbreaks; Humans; Infant; Infant, Newborn; SARS-CoV-2; Severe Acute Respiratory Syndrome; Systemic Inflammatory Response Syndrome","Rajapakse","Nipunie","Division of Pediatric Infectious Diseases, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA",NA
"78","32577668","10.1101/2020.04.19.20069922","Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, and Time-to-Event Outcomes.","Time is of the essence in evaluating potential drugs and biologics for the treatment and prevention of COVID-19. There are currently over 400 clinical trials (phase 2 and 3) of treatments for COVID-19 registered on clinicaltrials.gov. Covariate adjustment is a statistical analysis method with potential to improve precision and reduce the required sample size for a substantial number of these trials. Though covariate adjustment is recommended by the U.S. Food and Drug Administration and the Europ","2021","01","10","medRxiv","medRxiv : the preprint server for health sciences",NA,"Benkeser","David","Department of Biostatistics and Bioinformatics, Emory University",NA
"79","32577634","10.1101/2020.06.11.145920","SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.","A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both po","2021","01","10","bioRxiv","bioRxiv : the preprint server for biology",NA,"Corbett","Kizzmekia S","Vaccine Research Center",NA
"80","32575350","10.3390/vaccines8020320","Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients.","Corona Virus Disease 2019 (COVID-19) has affected over 8 million people worldwide. We underscore the potential benefits of conducting a randomized open-label unblinded clinical trial to evaluate the role of ursodeoxycholic acid (UDCA) in the treatment of COVID-19. Some COVID-19 patients are characterized with cytokine storm syndrome that can cause severe and irreversible damage to organs leading to multi-organ failure and death. Therefore, it is critical to control both programmed cell death (ap","2020","09","28","Vaccines (Basel)","Vaccines","COVID-19; Coronavirus; clinical trial; cytokine storm; ursodeoxycholic acid","Subramanian","Subbaya","Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA",NA
"81","32574267","10.3389/fimmu.2020.01196","COVID-19 and SARS Coronavirus 2: Antibodies for the Immediate Rescue and Recovery Phase.",NA,"2020","07","10","Front Immunol","Frontiers in immunology","SARS Coronavirus 2 and Covid-19 immunity; SARS-CoV-2 immunity; antibody protection for Covid-19; antibody therapy for Covid-19; convalescent plasma for Covid-19 therapy; gamma globulin for Covid-19 protection; human volunteer testing for Covid-19 protection; vaccine and therapeutics testing for Covid-19; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Immunization, Passive; Pandemics; Pneumonia, Viral; SARS-CoV-2","Halstead","Scott B","Independent Researcher, Bethesda, MD, United States",NA
"82","32574236","10.3389/fphar.2020.00791","Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?","The novel coronavirus strain, severe acute respiratory syndrome coronavirus-2, the causative agent of COVID-19 emerged in Wuhan, China, in December 2019 and is skyrocketing throughout the globe and become a global public health emergency. Despite promising preventive measures being taken, there is no vaccine or drug therapy officially approved to prevent or treat the infection. Everybody is waiting the findings of ongoing clinical trials in various chemical and biological products. This review i","2020","09","28","Front Pharmacol","Frontiers in pharmacology","COVID-19; GS-5734; RdRp; SARS-CoV-2; remdesivir","Sisay","Mekonnen","Department of Pharmacology and Toxicology, School of Pharmacy, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia",NA
"83","32571773","10.3399/bjgp20X711941","Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018.","Patients infected with the novel coronavirus (SARS-CoV-2) are being treated empirically with oseltamivir, but there is little evidence from randomised controlled trials to support the treatment of coronavirus infections with oseltamivir. To determine whether adding oseltamivir to usual care reduces time to recovery in symptomatic patients who have tested positive for coronavirus (not including SARS-CoV-2). Exploratory analysis of data from an open-label, pragmatic, randomised controlled trial du","2020","07","17","Br J Gen Pract","The British journal of general practice : the journal of the Royal College of General Practitioners","COVID-19; Europe; coronavirus; oseltamivir; primary care; randomised controlled trial; Adolescent; Adult; Aged; Antiviral Agents; COVID-19; Child; Coronavirus Infections; Drug Therapy, Combination; Europe; Female; Fever; Headache; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Pandemics; Pneumonia, Viral; Time Factors; Treatment Outcome; Young Adult","Coenen","Samuel","Centre for General Practice, Department of Family Medicine &amp",NA
"84","32571007","10.1021/acsnano.0c04006","Nanotechnology for COVID-19: Therapeutics and Vaccine Research.","The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this &quot;virus&quot; nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using en","2020","09","01","ACS Nano","ACS nano","combination drug delivery; coronavirus disease 2019; immunopathology; nanomedicine; repurposed nanotechnology; severe acute respiratory syndrome coronavirus 2 structure; targeted therapeutics; vaccine adjuvant nanoparticles; vaccine nanocarriers; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Mass Vaccination; Nanotechnology; Pandemics; Pneumonia, Viral; Viral Vaccines","Chauhan","Gaurav","School of Engineering and Sciences, Tecnologico de Monterrey, Av. Eugenio Garza Sada 2501 Sur, 64849 Monterrey, Nuevo Le..n, Mexico",NA
"85","32567818","10.1111/irv.12775","Respiratory viral coinfection in a birth cohort of infants in rural Nepal.","Acute respiratory illnesses are a leading cause of global morbidity and mortality in children. Coinfection with multiple respiratory viruses is common. Although the effects of each virus have been studied individually, the impacts of coinfection on disease severity are less understood. A secondary analysis was performed of a maternal influenza vaccine trial conducted between 2011 and 2014 in Nepal. Prospective weekly household-based active surveillance of infants was conducted from birth to 180.","2020","11","03","Influenza Other Respir Viruses","Influenza and other respiratory viruses","coinfection; epidemiology; global health; human influenza; human respiratory syncytial virus; respiratory infections; Coinfection; Fever; Humans; Infant; Infant, Newborn; Nepal; Odds Ratio; Prospective Studies; Respiratory Tract Infections; Rural Population; Virus Diseases; Viruses","Emanuels","Anne","Department of Epidemiology, University of Washington, Seattle, WA, USA",NA
"86","32565096","10.1016/j.jpeds.2020.06.048","Anticipating Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Testing, Licensure, and Recommendations for Use.",NA,"2020","09","11","J Pediatr","The Journal of pediatrics","Betacoronavirus; COVID-19; COVID-19 Vaccines; Child; Clinical Trials as Topic; Coronavirus Infections; Drug Approval; Drug Industry; Humans; Pandemics; Patient Safety; Pneumonia, Viral; SARS-CoV-2; United States; United States Food and Drug Administration; Viral Vaccines","Edwards","Kathryn M","Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN. Electronic address: Kathryn.edwards@vumc","Kathryn.edwards@vumc.org"
"87","32563999","10.1136/postgradmedj-2020-138234","Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19).","Coronavirus has emerged as a global health threat due to its accelerated geographic spread over the last two decades. This article reviews the current state of knowledge concerning the origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Historically, it has caused two pandemics: severe acute respiratory syndrome and Middle East respiratory syndrome followed by the present COVID-19 that emerged from China. The virus is believed to be acquired from zoonotic sourc","2020","12","04","Postgrad Med J","Postgraduate medical journal","Basic sciences; Education and training (see medical education &amp; training); Hepatobiliary surgery; Histopathology; Medical education and training; Pathology; Surgery; Transplant surgery; Antiviral Agents; COVID-19; COVID-19 Nucleic Acid Testing; COVID-19 Vaccines; Coronavirus; Disease Management; Extracorporeal Membrane Oxygenation; Humans; Lung; Middle East Respiratory Syndrome Coronavirus; SARS Virus; SARS-CoV-2; Tomography, X-Ray Computed","Umakanthan","Srikanth","Paraclinical Sciences, The University of the West Indies at Saint Augustine Faculty of Medical Sciences, Saint Augustine, Trinidad and Tobago Srikanth.Umakanthan@sta.uwi.edu dr.u.srikanth@gmail","Srikanth.Umakanthan@sta.uwi.edu"
"88","32563940","10.1016/j.dsx.2020.06.024","Analyzing barriers for implementation of public health and social measures to prevent the transmission of COVID-19 disease using DEMATEL method.","COVID-19 is a contagious disease caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Till now there are no vaccines and explicit medicines available for the treatment of COVID-19 disease, therefore the initiatives like public health and social measures are helpful in limiting the quantity of contaminations and saving lives. Keeping this in view, an attempt has been made in the present work to identify the barriers which hinder the implementation of ","2020","09","28","Diabetes Metab Syndr","Diabetes &amp; metabolic syndrome","Barriers; COVID-19; DEMATEL; Public health and social (PHS) measures; Betacoronavirus; COVID-19; Coronavirus Infections; Decision Support Techniques; Health Plan Implementation; Humans; Models, Theoretical; Pandemics; Pneumonia, Viral; Public Health; SARS-CoV-2","Maqbool","Annayath","Department of Mechanical Engineering, National Institute of Technology Srinagar, Jammu and Kashmir, 190006, India. Electronic address: annayat_13phd19@nitsri","13phd19@nitsri.net"
"89","32563547","10.1016/j.jaut.2020.102506","Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.","Coronavirus disease 2019 (COVID-19) has been categorized as evolving in overlapping phases. First, there is a viral phase that may well be asymptomatic or mild in the majority, perhaps 80% of patients. The pathophysiological mechanisms resulting in minimal disease in this initial phase are not well known. In the remaining 20% of cases, the disease may become severe and/or critical. In most patients of this latter group, there is a phase characterized by the hyperresponsiveness of the immune syst","2020","10","27","J Autoimmun","Journal of autoimmunity","Antiphospholipid syndrome; Autoimmunity; COVID-19; Cytokine storm syndrome; Cytopenia; Guillain-Barr.. syndrome; Kawasaki disease; SARS-CoV-2; Vaccines; Adaptive Immunity; Autoimmune Diseases; Betacoronavirus; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Coronavirus Infections; Critical Illness; Cytokine Release Syndrome; Female; Genetic Predisposition to Disease; Humans; Immunity, Innate; Immunization, Passive; Inflammation Mediators; Macrophage Activation; Male; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors","Rodr..guez","Yhojan","Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia",NA
"90","32562594","10.1002/eahr.500060","Pregnant Women in Trials of Covid-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials.","Ethical issues abound during this unprecedented international public health crisis of Covid-19. While the trade-off between societal and individual interests that occurs at the intersection of public health ethics and clinical ethics affects all populations, this calculus has particular relevance for pregnant women and the question of when they will have access to new Covid-19 therapies and vaccines. Pregnant women are a &quot;scientifically complex&quot; population whose inclusion in clinical r","2020","07","27","Ethics Hum Res","Ethics &amp; human research","Covid-19 clinical trials; human subjects research; inclusion of pregnant women in trials; maternal-fetal ethics; pregnant research participants; research with pregnant women; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Female; Health Policy; Humans; Pandemics; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; Research Subjects; SARS-CoV-2; United States","Farrell","Ruth","Vice chair of research in the OB/GYN &amp",NA
"91","32562316","10.1096/fj.202001351","A proposed role for the SARS-CoV-2 nucleocapsid protein in the formation and regulation of biomolecular condensates.","To date, the recently discovered SARS-CoV-2 virus has afflicted &gt;6.9 million people worldwide and disrupted the global economy. Development of effective vaccines or treatments for SARS-CoV-2 infection will be aided by a molecular-level understanding of SARS-CoV-2 proteins and their interactions with host cell proteins. The SARS-CoV-2 nucleocapsid (N) protein is highly homologous to the N protein of SARS-CoV, which is essential for viral RNA replication and packaging into new virions. Emerging","2020","12","11","FASEB J","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","enveloped viruses; liquid-liquid phase separation; low-complexity domain; stress granule; viral capsid; Binding Sites; Computational Biology; Coronavirus Nucleocapsid Proteins; Cytoplasmic Granules; Humans; Phosphoproteins; Protein Binding; Protein Domains; Protein Kinases; SARS-CoV-2; Virus Assembly; Virus Replication","Cascarina","Sean M","Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO, USA",NA
"92","32561657","10.1128/mBio.00907-20","Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?","We propose the concept that administration of an unrelated live attenuated vaccine, such as MMR (measles, mumps, rubella), could serve as a preventive measure against the worst sequelae of coronavirus disease 2019 (COVID-19). There is mounting evidence that live attenuated vaccines provide nonspecific protection against lethal infections unrelated to the target pathogen of the vaccine by inducing &quot;trained&quot; nonspecific innate immune cells for improved host responses against subsequent i","2020","06","29","mBio","mBio","COVID-19; MMR; clinical trial; inflammation; live attenuated vaccines; myeloid-derived suppressor cells; sepsis; trained innate immunity; BCG Vaccine; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Cross Protection; Humans; Measles; Measles-Mumps-Rubella Vaccine; Mumps; Mycobacterium bovis; Pandemics; Pneumonia, Viral; Rubella; SARS-CoV-2; Vaccination; Vaccines, Attenuated","Fidel","Paul L","Department of Oral and Craniofacial Biology, Louisiana State University Health-School of Dentistry, New Orleans, Louisiana, USA pfidel@lsuhsc","pfidel@lsuhsc.edu"
"93","32557771","10.1111/bcp.14435","How to expedite early-phase SARS-CoV-2 vaccine trials in pandemic setting-A practical perspective.",NA,"2021","04","30","Br J Clin Pharmacol","British journal of clinical pharmacology",NA,"van der Plas","Johan L","Centre for Human Drug Research (CHDR), Leiden, The Netherlands",NA
"94","32554907","","Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials.","COVID-19 has become one of the biggest health concern, along with huge economic burden. With no clear remedies to treat the disease, doctors are repurposing drugs like chloroquine and remdesivir to treat COVID-19 patients. In parallel, research institutes in collaboration with biotech companies have identified strategies to use viral proteins as vaccine candidates for COVID-19. Although this looks promising, they still need to pass the test of challenge studies in animal models. As various model","2020","06","25","J Biosci","Journal of biosciences","Animal Experimentation; Animals; COVID-19; Coronavirus Infections; Humans; Models, Animal; Pandemics; Pneumonia, Viral; Viral Vaccines","Deb","Bijayeeta","Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati 517 507, India",NA
"95","32554572","10.1126/science.368.6497.1295","Pandemic vaccines are about to face the real test.",NA,"2020","07","08","Science","Science (New York, N.Y.)","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Global Health; Humans; Pandemics; Placebos; Pneumonia, Viral; Viral Vaccines; World Health Organization","Cohen","Jon",NA,NA
"96","32548679","10.1007/s00228-020-02933-w","Calling for an exponential escalation scheme in vaccine development for COVID-19.","COVID-19 as a pandemic calls for rapid development of vaccines. Here a proposal of a seamless, adaptive, phase 1-3 trial for accelerated vaccine development is described. Starting at 10, the number of vaccinated volunteers would exponentially increase by tenfold at an interval of 2..weeks; close surveillance of antibody responses, safety and efficacy is necessary. After only 16..weeks, general vaccination would be feasible if supply meets the demand. A COVID-19 vaccine would be rapidly available","2020","09","23","Eur J Clin Pharmacol","European journal of clinical pharmacology","Adaptive design; COVID-19; Exponential growth; Seamless trial design; Vaccination; Betacoronavirus; Biomedical Research; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Wehling","Martin","Institute of Clinical Pharmacology Mannheim, Medical Faculty Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. martin.wehling@medma.uni-heidelberg","martin.wehling@medma.uni"
"97","32544799","10.1016/j.ejca.2020.05.026","Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019.","While confirmed cases of the deadly coronavirus disease 2019 (COVID-19) have exceeded 4.7 million globally, scientists are pushing forward with efforts to develop vaccines and treatments in an attempt to slow the pandemic and lessen the disease's damage. Although no proven effective therapies for treating patients with COVID-19 or for managing their complications currently exist, the rapidly expanding knowledge regarding severe acute respiratory syndrome coronavirus 2 and its interplay with host","2020","07","28","Eur J Cancer","European journal of cancer (Oxford, England : 1990)","Anti...IL-6R; Anti...PD-1; COVID-19; Cytokine storm; Pembrolizumab; SARS-CoV-2; Tocilizumab; Antibodies, Monoclonal, Humanized; Apoptosis; B7-H1 Antigen; Betacoronavirus; COVID-19; Coronavirus Infections; Host-Pathogen Interactions; Humans; Immunologic Factors; Lymphopenia; Neoplasms; Pandemics; Pneumonia, Viral; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; SARS-CoV-2; T-Lymphocytes; Treatment Outcome","Di Cosimo","Serena","Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy",NA
"98","32540733","10.1016/j.dsx.2020.06.016","Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies.","Many patients with coronavirus disease 2019 (COVID-19) have comorbidities related to metabolic syndrome (MS) during the disease course. Its presence in different ethnicities and continents places MS as an important risk factor for COVID-19. Adequate understanding of the interplay between MS, COVID-19 and proposed therapies is required for optimum management of these patients. We systematically searched the PubMed and Google Scholar databases until June 1st, 2020 and accessed the full text on COV","2020","09","24","Diabetes Metab Syndr","Diabetes &amp; metabolic syndrome","COVID-19; Cardiovascular disease; Diabetes; Drugs; Liver disease; Metabolic syndrome; Obesity; Betacoronavirus; COVID-19; Comorbidity; Coronavirus Infections; Disease Progression; Humans; Metabolic Syndrome; Pandemics; Pneumonia, Viral; Prognosis; Risk Factors; SARS-CoV-2; Severity of Illness Index","Costa","Fernanda Farias","Department of Biomedicine, CEUMA University (UNICEUMA), R. Bar..o do Rio Branco, 100, Entroncamento, Imperatriz, MA, 65903-093, Brazil",NA
"99","32540367","10.1016/j.retram.2020.05.004","A review of potential treatments to date in COVID-19 patients according to the stage of the disease.","Since the end of 2019, the COVID-19 pandemic has affected millions of people worldwide. With the rapid spread of this virus, an immense burden has fallen upon both healthcare and economic systems. As a consequence, there is an unprecedented urgency for researchers and scientific committees from all over the world to find an effective treatment and vaccine. Many potential therapies are currently under investigation, with some, like Hydroxychloroquine, being authorized for emergency use in some co","2020","09","02","Curr Res Transl Med","Current research in translational medicine","COVID-19; Pathophysiology; Treatment; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome; Viral Vaccines","Alsuliman","Tamim","Service d'H..matologie, h..pital Saint-Antoine, AP-HP, Sorbonne Universit.., 75012, Paris, France. Electronic address: dr.tameem.soliman@gmail","dr.tameem.soliman@gmail.com"
"100","32535032","10.1016/j.jsbmb.2020.105719","Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBMB 2020_166.","Coronavirus infection is a serious health problem awaiting an effective vaccine and/or antiviral treatment. The major complication of coronavirus disease 2019 (COVID-19), the Acute Respiratory Distress syndrome (ARDS), is due to a variety of mechanisms including cytokine storm, dysregulation of the renin-angiotensin system, neutrophil activation and increased (micro)coagulation. Based on many preclinical studies and observational data in humans, ARDS may be aggravated by vitamin D deficiency and","2020","09","14","J Steroid Biochem Mol Biol","The Journal of steroid biochemistry and molecular biology","1.., 25(OH)2D or 1.., 25-dihydroxyvitamin D or calcitriol; Acute respiratory distress syndrome (ARDS); Calcifediol or 25-hydroxyvitamin D3; Corona virus; Cytokine storm; Hypercoagulability; Lung diseases; Renin-angiotensin system; SARS-CoV-2; Vitamin D, vitamin D3 or cholecalciferol; Administration, Oral; Betacoronavirus; COVID-19; Calcifediol; Coronavirus Infections; Humans; Pandemics; Pilot Projects; Pneumonia, Viral; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Respiratory Distress Syndrome; SARS-CoV-2; Vitamin D; Vitamin D Deficiency; Vitamins","Quesada-Gomez","Jose Manuel","Instituto Maim..nides de Investigaci..n Biom..dica de C..rdoba (IMIBIC). Hospital Universitario Reina Sof..a, Universidad de C..rdoba, Fundaci..n Progreso y Salud, Avda. Men..ndez Pidal s/n, 14004, C..rdoba, Spain",NA
"101","32529703","10.1111/maq.12587","The WetNet: What the Oral Polio Vaccine Hypothesis Exposes about Globalized Interspecies Fluid Bonds.","The author analyzes the aftermath of Edward..Hooper's suggestion that the trial of an oral polio vaccine (OPV) in the Belgian colonies of Africa engendered the pandemic form of the AIDS virus, HIV-1. In response to..Hooper's book,..The River (1999),..the Royal Society in London held a conference to debate the origins of HIV. Examination of the quick dismissal of the OPV theory opens a space for legitimately challenging the widely held belief that the vaccine contamination question was convincing","2021","01","26","Med Anthropol Q","Medical anthropology quarterly","Africa; HIV origins; The WetNet; experimentality; zoonosis; Africa; Animals; Anthropology, Medical; COVID-19; Culture; HIV Infections; HIV-1; History, 20th Century; Humans; Internationality; Poliomyelitis; Poliovirus Vaccine, Oral; SARS-CoV-2; Vaccination","Jain","S Lochlann","Department of Anthropology, Stanford University",NA
"102","32527823","10.1126/science.abc8993","Aggregating data from COVID-19 trials.",NA,"2020","06","17","Science","Science (New York, N.Y.)","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Data Aggregation; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Ogburn","Elizabeth L","Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. eogburn@jhsph","eogburn@jhsph.edu"
"103","32527819","10.1126/science.abc4262","Can existing live vaccines prevent COVID-19?",NA,"2020","06","17","Science","Science (New York, N.Y.)","COVID-19; Coronavirus Infections; Humans; Mass Vaccination; Pandemics; Pneumonia, Viral; Poliovirus Vaccine, Oral; Randomized Controlled Trials as Topic; Vaccines, Attenuated; Vaccines, Live, Unattenuated","Chumakov","Konstantin","Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. konstantin.chumakov@fda.hhs","konstantin.chumakov@fda.hhs.gov"
"104","32527804","10.1126/science.abd2220","COVID-19 and flu, a perfect storm.",NA,"2020","06","17","Science","Science (New York, N.Y.)","COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Influenza Vaccines; Influenza, Human; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Time Factors; Uncertainty; Vaccination; Viral Vaccines","Belongia","Edward A","Edward A. Belongia is the director of the Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA. belongia.edward@marshfieldclinic","belongia.edward@marshfieldclinic.org"
"105","32526507","10.1016/j.mehy.2020.109802","Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19.","The ongoing pandemic of COVID-19 infection demands efforts to reduce spread. In order to eradicate an infectious disease, a method of prevention with low social cost is the most effective way. While we wait for new therapies and a vaccine, we are proposing a solution based on the existing knowledge in biomedical sciences. Here we propose to use low doses of hydroxychloroquine (50-100..mg daily orally) and intranasal interferon alpha-2b (IFN ..-2b) spray (0.5......10<sup>6</sup> IU twice daily) f","2020","12","22","Med Hypotheses","Medical hypotheses","Antiviral Agents; COVID-19; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hydroxychloroquine; Interferon alpha-2; Models, Theoretical; Randomized Controlled Trials as Topic; Recombinant Proteins; Treatment Outcome","Yang","Alexander","Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI 48202, USA",NA
"106","32525830","10.3855/jidc.12744","A vaccine is not too far for COVID-19.",NA,"2020","06","22","J Infect Dev Ctries","Journal of infection in developing countries","COVID-19; SARS-CoV-2; vaccines; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Patel","Shailesh Kumar","Division of Pathology, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India. shaileshpatel624@gmail","shaileshpatel624@gmail.com"
"107","32520683","10.2174/1389200221666200610172929","Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19.","As the number of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infected people is greatly increasing worldwide, the international medical situation becomes very serious. Potential therapeutic drugs, vaccine and stem cell replacement methods are emerging, so it is urgent to find specific therapeutic drugs and the best treatment regimens. After the publications on hydroxychloroquine (HCQ) with anti- SARS-COV-2 activity in vitro, a small, non-randomized, open-label clinical trial sho","2020","10","08","Curr Drug Metab","Current drug metabolism","COVID-19; SARS-CoV-2; clinical pharmacology; drug interaction; hydroxychloroquine; safety; Antiviral Agents; COVID-19; Coronavirus Infections; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Treatment Outcome","Cui","Cheng","Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China",NA
"108","32516839","10.1111/vox.12968","Early experience with convalescent plasma as immunotherapy for COVID-19 in China: Knowns and unknowns.","In the absence of a vaccine or specific drug treatment options for coronavirus disease (COVID-19), attention has been shifted in China to the possible therapeutic use of convalescent plasma. COVID-19 convalescent plasma (CCP) is currently under investigation. We summarized clinical studies and other research data available as of 5 May 2020 on CCP therapy according to the Clinical Treatment Guideline of COVID-19 Convalescent Plasma in China, as well as clinical experience at the First Affiliated ","2020","10","15","Vox Sang","Vox sanguinis","COVID-19; COVID-19 convalescent plasma (CCP); SARS-CoV-2; therapy; COVID-19; China; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunization, Passive; Pandemics; Pneumonia, Viral; Treatment Outcome","Chen","Binzhen","Department of Transfusion Medicine, Huashan Hospital, Fudan University, Shanghai, China",NA
"109","32515685","10.1080/22221751.2020.1772677","Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19.","Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and quickly spread globally. In this study, we investigated the characteristics of viral shedding from different sites and the neutralizing antibody (NAb) response during the acute and convalescent phases of nine children with COVID-19. SARS-CoV-2 was detected in their nasopharyngeal swabs (9/9, 100%), stool samples (8/9, 89%), and oropharyngeal swabs (3/9, 33%) but was not","2020","06","12","Emerg Microbes Infect","Emerging microbes &amp; infections","COVID-19; Children; SARS-CoV-2; neutralizing antibody; viral shedding; Antibodies, Neutralizing; Betacoronavirus; COVID-19; Child; Child, Preschool; Coronavirus Infections; Feces; Female; Humans; Infant; Inhibitory Concentration 50; Male; Nasopharynx; Oropharynx; Pandemics; Pneumonia, Viral; RNA, Viral; SARS-CoV-2; Time Factors; Virus Shedding","Liu","Pengcheng","Department of Clinical Laboratory, Children's Hospital of Fudan University, Shanghai, People's Republic of China",NA
"110","32515404","10.5455/JPMA.37","Comprehensive overview of COVID-19 clinical trials.","Here, we present an overview of the clinical trials that are currently being conducted or have concluded to date on COVID-19 globally. A comprehensive search was conducted to present 16 trial registries from around the world. Collectively, there are 1,528 trials reported for COVID-19 to date. Out of them, 50 studies included paediatric age group from day 0 to less than or equal to 18 years of age. A few 18 studies involve only females and 20 only males. There are 2 trials currently underway in B","2020","06","18","J Pak Med Assoc","JPMA. The Journal of the Pakistan Medical Association","Coronavirus, 2019-nCoV, SARS-CoV-2, 2019nCoV, Clinical Trial, Asia.; Asia, Western; Betacoronavirus; COVID-19; Clinical Studies as Topic; Coronavirus Infections; Female; Humans; Male; Pandemics; Pneumonia, Viral; SARS-CoV-2","Ejaz","Kiran","School of Medicine, Emory University Atlanta, GA, USA",NA
"111","32513202","10.1186/s12961-020-00571-3","From COVID-19 research to vaccine application: why might it take 17...months not 17...years and what are the wider lessons?","It is often said that it takes 17...years to move medical research from bench to bedside. In a coronavirus disease (COVID-19) world, such time-lags feel intolerable. In these extraordinary circumstances could years be made into months? If so, could those lessons be used to accelerate medical research when the crisis eases?To measure time-lags in health and biomedical research as well as to identify ways of reducing them, we developed and published (in 2015) a matrix consisting of overlapping tra","2020","06","11","Health Res Policy Syst","Health research policy and systems","COVID-19; Coronavirus disease; Matrix; Pandemic; Research translation; SARS-CoV-2; Time-lags; Timescales; Trials; Vaccine; World Health Organization; Betacoronavirus; Biomedical Research; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Drug Approval; Drug Discovery; Humans; Pandemics; Pneumonia, Viral; Risk Assessment; SARS-CoV-2; Time Factors; Translational Medical Research; Viral Vaccines","Hanney","Stephen R","Health Economics Research Group, Brunel University London, Kingston Lane, Uxbridge, UK. stephen.hanney@brunel.ac","stephen.hanney@brunel.ac.uk"
"112","32511680","10.1001/jama.2020.9222","Anthony Fauci, MD, on COVID-19 Vaccines, Schools, and Larry Kramer.",NA,"2020","09","21","JAMA","JAMA","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; National Institutes of Health (U.S.); Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; United States; Viral Vaccines","Abbasi","Jennifer",NA,NA
"113","32511340","10.1101/2020.05.13.093195","ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques.","Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in December 2019<sup>1,2</sup> and is responsible for the COVID-19 pandemic<sup>3</sup>. Vaccines are an essential countermeasure urgently needed to control the pandemic<sup>4</sup>. Here, we show that the adenovirus-vectored vaccine ChAdOx1 nCoV-19, encoding the spike protein of SARS-CoV-2, is immunogenic in mice, eliciting a robust humoral and cell-mediated response. This response was not Th2 dominated, as demonstrated by IgG","2021","03","17","bioRxiv","bioRxiv : the preprint server for biology",NA,"van Doremalen","Neeltje","Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA",NA
"114","32511333","10.1101/2020.03.20.000141","COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning.","To ultimately combat the emerging COVID-19 pandemic, it is desired to develop an effective and safe vaccine against this highly contagious disease caused by the SARS-CoV-2 coronavirus. Our literature and clinical trial survey showed that the whole virus, as well as the spike (S) protein, nucleocapsid (N) protein, and membrane protein, have been tested for vaccine development against SARS and MERS. We further used the Vaxign reverse vaccinology tool and the newly developed Vaxign-ML machine learn","2021","01","10","bioRxiv","bioRxiv : the preprint server for biology",NA,"Ong","Edison","Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA",NA
"115","32507409","10.1016/j.vaccine.2020.05.064","Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.","A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six","2020","06","22","Vaccine","Vaccine","Animal models; COVID-19; Enhanced disease; MERS-CoV vaccine; SARS-CoV-1 vaccine; SARS-CoV-2; SARS-CoV-2 vaccine; Vaccine adjuvants; Vaccine safety; Animals; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Disease Models, Animal; Humans; Pandemics; Pneumonia, Viral; Risk Assessment; SARS-CoV-2; Severe Acute Respiratory Syndrome; Viral Vaccines","Lambert","Paul-Henri","Centre of Vaccinology, University of Geneva, Switzerland",NA
"116","32505245","10.1016/S0140-6736(20)31252-6","COVID-19 vaccine development pipeline gears up.",NA,"2020","06","10","Lancet","Lancet (London, England)","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vaccines, Attenuated; Vaccines, DNA; Vaccines, Subunit; Viral Vaccines","Mullard","Asher",NA,NA
"117","32503874","10.1136/bmjopen-2020-039159","Efficacy of remdesivir in patients with COVID-19: a protocol for systematic review and meta-analysis of randomised controlled trials.","Despite global containment measures to fight the coronavirus disease 2019 (COVID-19), the pandemic continued to rise, rapidly spread across the world, and resulting in 2.6...million confirmed cases and 185 061 deaths worldwide as of 23 April 2020. Yet, there are no approved vaccines or drugs to make the disease less deadly, while efforts are underway. Remdesivir, a nucleotide-analogue antiviral drug developed for Ebola, is determined to prevent and stop infections with COVID-19, while results ar","2020","06","16","BMJ Open","BMJ open","clinical trials; infection control; respiratory infections; virology; Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Infection Control; Meta-Analysis as Topic; Pandemics; Pneumonia, Viral; Research Design; SARS-CoV-2; Systematic Reviews as Topic; Treatment Outcome","Gebrie","Desye","School of Pharmacy, College of Health Sciences, Mekelle University, Mekelle, Ethiopia desye.gebrie@mu.edu","desye.gebrie@mu.edu.et"
"118","32503817","10.21873/invivo.11949","Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.","Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), initially termed 2019-new CoV (2019-nCoV), is a novel coronavirus responsible for the severe respiratory illness currently ongoing worldwide from the beginning of December 2019. This beta gene virus, very close to bat coronaviruses (bat-CoV-RaTG13) and bat-SL-CoVZC45, causes a severe disease, similar to those caused by Middle East respiratory syndrome (MERS)-CoV and SARS-CoV viruses, featured by low to moderate mortality rate. Unfortu","2020","06","22","In Vivo","In vivo (Athens, Greece)","COVID-19; SARS-Cov-2; antiviral drugs; coronaviruses; review; tocilizumab; virus; Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; COVID-19; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Humans; Indoles; Lopinavir; Multicenter Studies as Topic; Neuraminidase; Pandemics; Pneumonia, Viral; Primates; Ribavirin; Ritonavir; SARS-CoV-2; Treatment Outcome","Bimonte","Sabrina","Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori - IRCCS - &quot","s.bimonte@istitutotumori.na.it"
"119","32503602","10.1186/s13063-020-04389-w","Two Randomized Controlled Trials of Bacillus Calmette-Gu..rin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials.","The objectives of these two separate trials are: (1) to reduce health care workers (HCWs) absenteeism; and (2) to reduce hospital admission among the elderly during the COVID-19 pandemic through BCG vaccination. Two separate multi-centre placebo-controlled parallel group randomized trials PARTICIPANTS: (1) Health care personnel working in the hospital or ambulance service where they will take care of patients with the COVID-19 infection and (2) elderly ...60 years. The HCW trial is being underta","2020","06","30","Trials","Trials","BCG-vaccine; COVID-19; Elderly; Health-Care Workers; Randomised controlled trial; protocol; Absenteeism; Adult; Aged; Aged, 80 and over; BCG Vaccine; Betacoronavirus; COVID-19; Coronavirus Infections; Female; Health Personnel; Hospitalization; Humans; Male; Middle Aged; Multicenter Studies as Topic; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Vaccination","Ten Doesschate","Thijs","University Medical Center, Utrecht, The Netherlands. t.tendoesschate@umcutrecht","t.tendoesschate@umcutrecht.nl"
"120","32501411","10.1038/s41420-020-0275-2","SARS-CoV-2 infection serology: a useful tool to overcome lockdown?","The outbreak of 2019 novel coronavirus disease (Covid-19) caused by SARS-CoV-2 has spread rapidly, inducing a progressive growth in infected patients number. Social isolation (lockdown) has been assessed to prevent and control virus diffusion, leading to a worldwide financial and political crisis. Currently, SARS-CoV-2 RNA detection in nasopharyngeal swab takes place by real-time PCR (RT-qPCR). However, molecular tests can give some false-negative results. In this context, serological assays can","2021","04","28","Cell Death Discov","Cell death discovery","Immunochemistry; Viral infection","Nuccetelli","Marzia","Tor Vergata University Hospital, Rome, Italy",NA
"121","32499154","10.1016/j.arcmed.2020.05.007","Covid-19 Pandemic and Current Medical Interventions.","First humanoid coronavirus was discovered in the middle of 1960s, the class of viruses are considered to be a huge threat. The first onset of human coronavirus, SARS (SARS-CoV) appeared in 2003 which spanned five continents having lethal effects on human population accompanied by The Middle East Respiratory Syndrome Coronavirus in 2012 with a death rate of 35%. The viruses remain a threat till date and are of serious concern since no vaccine or specified drug therapy has been approbated for trea","2020","09","28","Arch Med Res","Archives of medical research","Human coronavirus; SARS-CoV2; Structure; Therapy; Treatments; Virus; Animals; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Genome, Viral; Global Health; Host-Pathogen Interactions; Humans; Ligands; Pandemics; Pneumonia, Viral; Risk; SARS-CoV-2; Virus Replication","Manhas","Sweeta","Division of Biochemistry, Faculty of Basic Sciences, Sher-e-Kashmir University of Agricultural Sciences and Technology of Jammu, Main Campus Chatha, Jammu, J and K, India",NA
"122","32498742","10.1017/S096318012000047X","SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward.","The world awaits a SARS-CoV-2 virus (i.e., COVID-19 disease) vaccine to keep the populace healthy, fully reopen their economies, and return their social and healthcare systems to &quot;normal.&quot; Vaccine safety and efficacy requires meticulous testing and oversight; this paper describes how despite grandiose public statements, the current vaccine development, testing, and production methods may prove to be ethically dubious, medically dangerous, and socially volatile. The basic moral concern ","2021","01","11","Camb Q Healthc Ethics","Cambridge quarterly of healthcare ethics : CQ : the international journal of healthcare ethics committees","COVID-19; SARS-CoV-2 virus; immunization; vaccine testing; vaccines; Biomedical Research; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Development; Humans; Immunization Programs; SARS-CoV-2","Iserson","Kenneth V",NA,NA
"123","32498131","10.1002/cpt.1932","Pandemic Best Regulatory Practices: An Urgent Need in the COVID-19 Pandemic.","As large numbers of candidate drugs and vaccines for potential use in the coronavirus disease 2019 (COVID-19) pandemic are being investigated, medicine regulators globally must now make urgent, informed, contextually risk-1based decisions regarding clinical trials and marketing authorizations. They must do this with the flexibility demanded by the pandemic while maintaining their core risk assessment and public safety functions. We lay out the critical role of regulators in the current crisis an","2020","09","29","Clin Pharmacol Ther","Clinical pharmacology and therapeutics","Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Drug and Narcotic Control; Humans; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; SARS-CoV-2","Lumpkin","Murray M","The Bill and Melinda Gates Foundation, Seattle, Washington, USA",NA
"124","32496545","10.1001/jama.2020.9881","Challenge Trials-Could Deliberate Coronavirus Exposure Hasten Vaccine Development?",NA,"2020","09","21","JAMA","JAMA","COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Viral Vaccines; Volunteers","Rubin","Rita",NA,NA
"125","32496246","10.4103/ijph.IJPH_510_20","Impact of nonpharmacological interventions on COVID-19 transmission dynamics in India.","As of May 4, 2020, India has reported 42,836 confirmed cases and 1,389 deaths from COVID-19. India's multipronged response included nonpharmacological interventions (NPIs) like intensive case-based surveillance, expanding testing capacity, social distancing, health promotion, and progressive travel restrictions leading to a complete halt of international and domestic movements (lockdown). We studied the impact of NPI on transmission dynamics of COVID-19 epidemic in India and estimated the minimu","2020","06","17","Indian J Public Health","Indian journal of public health","COVID-19; India; reproduction number; severe acute respiratory syndrome coronavirus 2; Basic Reproduction Number; Betacoronavirus; COVID-19; Communicable Disease Control; Coronavirus Infections; Health Promotion; Humans; India; Pandemics; Pneumonia, Viral; Public Health Surveillance; SARS-CoV-2; Time Factors; Travel","Patel","Purvi","India Epidemic Intelligence Service Officer, National Centre for Disease Control, Delhi, India",NA
"126","32496238","10.4103/ijph.IJPH_520_20","COVID-19 vaccine development and the way forward.","The whole globe is reeling under the COVID-19 pandemic now. With the scale and severity of infection, number of deaths and lack of any definite therapeutic armamentarium, the vaccine development has been accelerated at a never-before pace. A wide variety of vaccine technologies and platforms are being attempted. Out of the over 108 efforts, 100 are in preclinical and eight in Phase 1 or 2 trial stage. While the availability of newer technologies has facilitated development, there are several cha","2020","06","17","Indian J Public Health","Indian journal of public health","COVID-19; Coronavirus; severe acute respiratory syndrome-CoV-2; technologies; vaccines development; Antiviral Agents; Betacoronavirus; Biomedical Research; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; India; Inflammation Mediators; Pandemics; Pneumonia, Viral; SARS-CoV-2; Time Factors; Viral Vaccines","Arora","Narendra Kumar","Executive Director, The INCLEN Trust International, New Delhi, India",NA
"127","32495979","10.1002/rmv.2116","Emergence of novel coronavirus and progress toward treatment and vaccine.","In late December 2019, a group of patients was observed with pneumonia-like symptoms that were linked with a wet market in Wuhan, China. The patients were found to have a novel coronavirus genetically related to a bat coronavirus that was termed SARS-CoV-2. The virus gradually spread worldwide and was declared a pandemic by WHO. Scientists have started trials on potential preventive and treatment options. Currently, there is no specific approved treatment for SARS-CoV-2, and various clinical tri","2020","07","20","Rev Med Virol","Reviews in medical virology","SARS-CoV-2; bat coronavirus; chloroquine; remdesivir; vaccine; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Khan","Muhammad Muzamil","Department of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan",NA
"128","32495226","10.1007/s10067-020-05202-4","Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?","The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical vent","2020","07","17","Clin Rheumatol","Clinical rheumatology","COVID-19; Chloroquine; Hydroxychloroquine; SARS-CoV-2; Antiviral Agents; Betacoronavirus; COVID-19; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2","Ib....ez","Sebasti..n","Medicine Faculty Cl..nica Alemana, Universidad del Desarrollo, Av. Manquehue Norte 1410, piso 7,, 7650567, Vitacura, Santiago, Chile. sibanez@alemana","sibanez@alemana.cl"
"129","32494546","10.7759/cureus.8342","Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials.","The ongoing novel coronavirus disease 2019 (COVID-19) pandemic has been responsible for millions of infections and hundreds of thousands of deaths. To date, there is no approved targeted treatment, and many investigational therapeutic agents and vaccine candidates are being considered for the treatment of COVID-19. To extract and summarize information on potential vaccines and therapeutic agents against COVID-19 at different stages of clinical trials from January to March 2020, we reviewed major","2020","09","28","Cureus","Cureus","2019 novel coronavirus; covid 19; drug therapeutics; sars-cov-2 (severe acute respiratory syndrome coronavirus -2); treatment choices; vaccines","Bhagavathula","Akshaya S","Public Health, Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, ARE",NA
"130","32493494","10.1186/s13063-020-04400-4","Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.","SARS-CoV-2 infection presents a high transmission in the group of health professionals in Spain (12-15% infected). Currently there is no accepted chemoprophylaxis but hydroxychloroquine (HDQ) is known to inhibit the coronavirus in vitro. Our hypothesis is that oral administration of hydroxychloroquine to healthcare professionals can reduce the incidence and prevalence of infection as well as its severity in this group. Design: Prospective, single center, double blind, randomised, controlled tria","2020","06","10","Trials","Trials","COVID-19; Chemoprophylaxis; Healthcare professionals; Hydroxychloroquine; Protocol; Randomised controlled trial; Adolescent; Adult; Aged; Antiviral Agents; Betacoronavirus; COVID-19; Chemoprevention; Coronavirus Infections; Double-Blind Method; Female; Humans; Hydroxychloroquine; Infectious Disease Transmission, Patient-to-Professional; Male; Middle Aged; Occupational Exposure; Occupational Health; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; SARS-CoV-2; Spain; Time Factors; Treatment Outcome; Young Adult","Cuadrado-Lav..n","Antonio","Department of Gastroenterology and Hepatology, Marqu..s de Valdecilla University Hospital, School of Medicine, University of Cantabria, Av. Valdecilla, 25, 39008, Santander, Cantabria, Spain",NA
"131","32493478","10.1186/s13063-020-04446-4","Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.","Primary Objective ... To test the efficacy of Hydroxychloroquine (HCQ) (400 mg orally daily for 3 days then 200 mg orally daily for an additional 11 days, to complete 14 days) to prevent incident SARS-CoV-2 infection, compared to ascorbic acid among contacts of persons with SARS-CoV-2 infection Secondary objectives ... To determine the safety and tolerability of HCQ as SARS-CoV-2 Post-exposure Prophylaxis (PEP) in adults ... To test the efficacy of HCQ (400 mg orally daily for 3 days then 200 mg","2020","06","10","Trials","Trials","COVID-19; Randomised controlled trial; health care worker; household contact; hydroxychloroquine; post-exposure prophylaxis; protocol; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Ascorbic Acid; Betacoronavirus; COVID-19; Contact Tracing; Coronavirus Infections; Drug Administration Schedule; Female; Humans; Hydroxychloroquine; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Occupational Exposure; Occupational Health; Pandemics; Pneumonia, Viral; Post-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; SARS-CoV-2; Time Factors; Treatment Outcome; United States; Virus Shedding; Young Adult","Barnabas","Ruanne V","Department of Global Health,International Clinical Research Center (ICRC), University of Washington, UW Box 359927, 325 Ninth Avenue, Seattle, WA, 98104, USA. rbarnaba@uw",NA
"132","32492743","10.1055/a-1114-3699","[SARS-CoV-2 infection (COVID-19): what can we expect?]","- Case numbers in China are clearly declining, case numbers in many European regions are no longer increasing exponentially.- Data on mortality from SARS-CoV-2 infection are contradictory; mortality is certainly lower than for SARS and MERS, but probably higher than for most seasonal flu outbreaks in recent years- The main complication of SARS-CoV-2 infection is pneumonia with development of acute respiratory distress syndrome (ARDS)- Asymptomatic and oligosymptomatic courses with virus shedding","2020","06","09","Dtsch Med Wochenschr","Deutsche medizinische Wochenschrift (1946)","COVID-19; Coronavirus Infections; Global Health; Humans; Pandemics; Pneumonia, Viral","Kern","Winfried V","Abteilung Infektiologie, Klinik f..r Innere Medizin II, Universit..tsklinikum Freiburg",NA
"133","32492144","10.1093/infdis/jiaa303","The Case for Why Africa Should Host COVID-19 Candidate Vaccine Trials.","In response to provocative comments by 2 European clinicians and scientists, the World Health Organization Director General has declared that Africa will not host COVID-19 vaccine trials. Such a stance risks stigmatizing COVID-19 vaccine trials in Africa and depriving Africa of critical research. To the contrary, there is a critical need for Africa to host COVID-19 vaccine trials on public health, scientific, and ethics grounds.","2020","07","21","J Infect Dis","The Journal of infectious diseases","COVID-19; ethics; global health; public health; vaccine trials; Africa; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Prevalence; Public Health; Viral Vaccines; World Health Organization","Singh","Jerome Amir","Centre for the AIDS Programme of Research in South Africa, Durban, South Africa",NA
"134","32489136","10.1177/0020764020932207","COVID-19 quarantine: Post-traumatic stress symptomatology among Lebanese citizens.","In the light of the global spread of the novel Coronavirus known as COVID-19 and in the absence of an approved treatment and vaccination, Lebanon has taken national measures, among which was home quarantine of the general public in an attempt to flatten the epidemic curve and avoid flooding the health care system. This study aimed at evaluating the prevalence of post-traumatic stress symptomatology (PTSS) during the times of COVID-19 quarantine among Lebanese citizens. This quantitative cross-se","2020","09","01","Int J Soc Psychiatry","The International journal of social psychiatry","COVID-19; Coronavirus; PTSS; pandemic; quarantine; Adolescent; Adult; Betacoronavirus; COVID-19; Coronavirus Infections; Cross-Sectional Studies; Evaluation Studies as Topic; Female; Humans; Lebanon; Male; Pandemics; Pneumonia, Viral; Prevalence; Quarantine; SARS-CoV-2; Stress Disorders, Post-Traumatic; Young Adult","Fawaz","Mirna","Nursing Department, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon",NA
